Charles Balch

Peer-Reviewed Articles

1. Liao, N, Li, C, Gradishar, WJ, Klimberg, VS, Roshal, JA, Yuan, TZ, Agarwala, SS, Valero, V, Swain, SM, Margenthaler, J, Rubio, IT, Hurvitz, S, Geyer, C, Lin, NU, Rugo, H, Zhang, Gc, Liu, N, Balch, CM. Accuracy and Reproducibility of ChatGPT Responses to Breast Cancer Tumor Board Patients. JCO Clinical Cancer Informatics 9, 2025. e-Pub 2025. PMID: 40466030.
2. Wagner P, Levine EA, Kim AC, Shen P, Fleming ND, Westin SN, Berry LK, Karakousis GC, Tanyi JL, Olson MT, Madajewski B, Ostrander B, Krishnan K, Balch CM, Bartlett DL. ASO Visual Abstract: Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent-Final Results from a Phase 2 Study. Ann Surg Oncol 31(7):4743-4744, 2024. e-Pub 2024. PMID: 38722420.
3. Wagner P, Levine EA, Kim AC, Shen P, Fleming ND, Westin SN, Berry LK, Karakousis GC, Tanyi JL, Olson MT, Madajewski B, Ostrander B, Krishnan K, Balch CM, Bartlett DL. Detection of Residual Peritoneal Metastases Following Cytoreductive Surgery Using Pegsitacianine, a pH-Sensitive Imaging Agent: Final Results from a Phase II Study. Ann Surg Oncol 31(7):4726-4734, 2024. e-Pub 2024. PMID: 38622456.
4. Hunt KK, Balch CM. Surgical Oncology Heroes and Legends: Charles M. Balch, MD, as Interviewed by Kelly K. Hunt, MD. Ann Surg Oncol 31(2):722-723, 2024. e-Pub 2023. PMID: 38062294.
5. Lin X, Sun W, Ren M, Xu Y, Wang C, Yan W, Kong Y, Balch CM, Chen Y. Prediction of nonsentinel lymph node metastasis in acral melanoma with positive sentinel lymph nodes. J Surg Oncol 128(8):1407-1415, 2023. e-Pub 2023. PMID: 37689989.
6. Liao N, Li C, Cao L, Chen Y, Ren C, Chen X, Mok H, Wen L, Li K, Wang Y, Zhang Y, Li Y, Lv J, Cao F, Luo Y, Li H, Wu W, Balch CM, Giuliano AE. Single-cell profile of tumor and immune cells in primary breast cancer, sentinel lymph node, and metastatic lymph node. Breast Cancer 30(1):77-87, 2023. e-Pub 2022. PMID: 36129636.
7. Brandt ML, O'Neill PJ, Shanafelt TD, Balch CM, Turner PL, McCann K, Mohan JE. Invited Commentary: Surgeon Wellness Must Become Our Collective Priority. J Am Coll Surg 236(1):265-268, 2023. e-Pub 2023. PMID: 36519922.
8. Petrelli NJ, Balch C. Dr. Constantine Karakousis: The Quintessential Surgical Oncologist. Ann Surg Oncol 29(13):7939-7941, 2022. e-Pub 2022. PMID: 36209327.
9. Wei X, Chen Y, Yao H, Wu D, Li H, Zhang R, Chi Z, Cui C, Bai X, Mao L, Qi Z, Li K, Lan S, Chen L, Guo R, Yao X, Lian B, Kong Y, Dai J, Tang B, Wang X, Gershenwald JE, Balch CM, Guo J, Si L. Prognostic impact of Breslow thickness in acral melanoma: A retrospective analysis. J Am Acad Dermatol. e-Pub 2022. PMID: 36075285.
10. Cui C, Lian B, Zhang X, Wu D, Li K, Si L, Yang Y, Tian H, Zhou L, Chi Z, Sheng X, Kong Y, Mao L, Wang X, Bai X, Yan X, Li S, Dai J, Tang B, Wei X, Gershenwald JE, Balch CM, Guo J. An Evidence-Based Staging System for Mucosal Melanoma: A Proposal. Ann Surg Oncol 29(8):5221-5234, 2022. e-Pub 2022. PMID: 35397739.
11. Zhang G, Ren C, Li C, Wang Y, Chen B, Wen L, Jia M, Li K, Mok H, Cao L, Chen X, Lin J, Wei G, Li Y, Zhang Y, Balch CM, Liao N. Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status. BMC Med 20(1):142, 2022. e-Pub 2022. PMID: 35484593.
12. Balch CM. The Politics of Recruiting Dr. R. Lee Clark Jr as the First Permanent Director of the University of Texas MD Anderson Hospital for Cancer Research : Part I: Creating the Texas Cancer Hospital and Events that Might Have Changed the Course of History (1941-1945). Ann Surg Oncol 29(1):719-732, 2022. e-Pub 2022. PMID: 34581922.
13. Balch CM. The Politics of Recruiting Dr. R Lee Clark Jr. as the First Permanent Director of The University of Texas MD Anderson Hospital for Cancer Research : Part II: The Process and Politics of Recruiting Lt. Colonel R. Lee Clark Jr. to The University of Texas MD Anderson Hospital. Ann Surg Oncol 29(1):733-749, 2022. e-Pub 2022. PMID: 34635973.
14. Balch CM. The MD Anderson Cancer Hospital That R. Lee Clark Built. Ann Surg Oncol 28(13):8087-8108, 2021. e-Pub 2021. PMID: 34125348.
15. Balch CM. Correction to: The Surgical Legacy of Randolph Lee Clark Jr, MD: First Surgeon-in-Chief and Director of University of Texas MD Anderson Cancer Center I. Training and Surgical Practice Before Recruitment to University of Texas MD Anderson Hospital. Ann Surg Oncol 28(Suppl 3):867, 2021. e-Pub 2021. PMID: 33532880.
16. Balch CM. The Surgical Legacy of Randolph Lee Clark, Jr, MD: First Director and Surgeon-in-Chief of University of Texas MD Anderson Cancer Center II. Surgical Practice and Leadership at University of Texas MD Anderson Cancer Center (1946-1978). Ann Surg Oncol 28(9):4794-4804, 2021. e-Pub 2021. PMID: 33515334.
17. Balch CM. The Surgical Legacy of Randolph Lee Clark Jr, MD: First Surgeon-in-Chief and Director of University of Texas MD Anderson Cancer Center I. Training and Surgical Practice Before Recruitment to University of Texas MD Anderson Hospital. Ann Surg Oncol 28(9):4782-4793, 2021. e-Pub 2021. PMID: 33469795.
18. Chen B, Zhang G, Lai J, Xiao W, Li X, Li C, Mok H, Li K, Wang Y, Cao L, Jia M, Ren C, Wen L, Wei G, Lin J, Li Y, Zhang Y, Chen X, Wu X, Zhang H, Li M, Liu J, Balch CM, Liao N. Genetic and immune characteristics of sentinel lymph node metastases and multiple lymph node metastases compared to their matched primary breast tumours. EBioMedicine 71:103542, 2021. e-Pub 2021. PMID: 34454403.
19. Elghazaly H, Aref AT, Anderson BO, Arun B, Yip CH, Abdelaziz H, Ghosn M, Al-Foheidi M, Cardenosa G, Leung JWT, Gado N, Balch CM, Sabry M, Ezz Elarab L, Giuliano AE, El-Zawahry HM, Abdel Karim K, Nasr A, Maki H, Chung H, Saadeddin A, Abdelwahab MM, Al Tahan FM, Chalabi N, Frolova M, Kamal RM, Shehata MA, Bahie Eldin N, Elghazawy H. The first BGICC consensus and recommendations for breast cancer awareness, early detection and risk reduction in low- and middle-income countries and the MENA region. Int J Cancer 149(3):505-513, 2021. e-Pub 2021. PMID: 33559295.
20. Elghazaly H, Rugo HS, Azim HA, Swain SM, Arun B, Aapro M, Perez EA, Anderson BO, Penault-Llorca F, Conte P, El Saghir NS, Yip CH, Ghosn M, Poortmans P, Shehata MA, Giuliano AE, Leung JWT, Guarneri V, Gligorov J, Gulluoglu BM, Abdel Aziz H, Frolova M, Sabry M, Balch CM, Orecchia R, El-Zawahry HM, Al-Sukhun S, Abdel Karim K, Kandil A, Paltuev RM, Foheidi M, El-Shinawi M, ElMahdy M, Abulkhair O, Yang W, Aref AT, Bakkach J, Bahie Eldin N, Elghazawy H. Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer. Cancers (Basel) 13(9), 2021. e-Pub 2021. PMID: 34066769.
21. Jia M, Liao N, Chen B, Zhang G, Wang Y, Li X, Cao L, Mok H, Ren C, Li K, Li C, Wen L, Lin J, Wei G, Balch CM. PIK3CA somatic alterations in invasive breast cancers: different spectrum from Caucasians to Chinese detected by next generation sequencing. Breast Cancer 28(3):644-652, 2021. e-Pub 2021. PMID: 33386585.
22. Wei X, Wu D, Li H, Zhang R, Chen Y, Yao H, Chi Z, Sheng X, Cui C, Bai X, Qi Z, Li K, Lan S, Chen L, Guo R, Yao X, Mao L, Lian B, Kong Y, Dai J, Tang B, Yan X, Wang X, Li S, Zhou L, Balch CM, Si L, Guo J. The Clinicopathological and Survival Profiles Comparison Across Primary Sites in Acral Melanoma. Ann Surg Oncol 27(9):3478-3485, 2020. e-Pub 2020. PMID: 32253677.
23. Li K, Liao N, Chen B, Zhang G, Wang Y, Guo L, Wei G, Jia M, Wen L, Ren C, Cao L, Mok H, Li C, Lin J, Chen X, Zhang Z, Hou T, Li M, Liu J, Balch CM, Liao N. Genetic mutation profile of Chinese HER2-positive breast cancers and genetic predictors of responses to Neoadjuvant anti-HER2 therapy. Breast Cancer Res Treat 183(2):321-332, 2020. e-Pub 2020. PMID: 32638235.
24. Hwang ES, Balch CM, Balch GC, Feldman SM, Golshan M, Grobmyer SR, Libutti SK, Margenthaler JA, Sasidhar M, Turaga KK, Wong SL, McMasters KM, Tanabe KK. Surgical Oncologists and the COVID-19 Pandemic: Guiding Cancer Patients Effectively through Turbulence and Change. Ann Surg Oncol 27(8):2600-2613, 2020. e-Pub 2020. PMID: 32535870.
25. Balch CM. Special Article Celebrating SSO 80th Anniversary: William Stewart MacComb-The Father of the Society of Surgical Oncology (SSO) and a Pioneering Surgical Oncologist. Ann Surg Oncol 27(7):2141-2148, 2020. e-Pub 2020. PMID: 32193716.
26. Balch CM, Harvey Sevier C. Origins of the National Comprehensive Cancer Network. J Natl Compr Canc Netw 18(5):499-502, 2020. e-Pub 2020. PMID: 32380456.
27. Debas H, Alatise OI, Balch CM, Brennan M, Cusack J, Donkor P, Jaffe BM, Mazariegos GV, Mock C, Mutiibwa D, Numann P, Nyagatuba JKM, O'Neill JA, Tarpley JL, Tesfaye S, Tefera G, Tuttle TM. Academic Partnerships in Global Surgery: An Overview American Surgical Association Working Group on Academic Global Surgery. Ann Surg 271(3):460-469, 2020. e-Pub 2020. PMID: 31592897.
28. Chen B, Zhang G, Wei G, Wang Y, Guo L, Lin J, Li K, Mok H, Cao L, Ren C, Wen L, Jia M, Li C, Hou T, Han-Zhang H, Liu J, Balch CM, Liao N. Heterogeneity of genomic profile in patients with HER2-positive breast cancer. Endocr Relat Cancer 27(3):153-162, 2020. e-Pub 2020. PMID: 31905165.
29. Wren SM, Balch CM, Doherty GM, Finlayson SR, Kauffman GL, Kibbe MR, Haider AH, Minter RM, Mock C, Muguti GI, Numann PJ, Olutoye OO, Roy N, Weigel RJ. Academic Advancement in Global Surgery: Appointment, Promotion, and Tenure: Recommendations From the American Surgical Association Working Group on Global Surgery. Ann Surg 271(2):279-282, 2020. e-Pub 2020. PMID: 31356270.
30. Rachidi S, Li H, Wallace K, Li Z, Balch C, Lautenschlaeger T. Preoperative platelet counts and postoperative outcomes in cancer surgery: a multicenter, retrospective cohort study. Platelets 31(1):79-87, 2020. e-Pub 2020. PMID: 30744463.
31. Lillemoe HA, Scally CP, Adams CL, Bednarski BK, Balch CM, Aloia TA, Gershenwald JE, Lee JE, Grubbs EG. Complex General Surgical Oncology Fellowship Applicants: Trends over Time and the Impact of Board Certification Eligibility. Ann Surg Oncol 26(9):2667-2674, 2019. e-Pub 2019. PMID: 31168736.
32. Zhang G, Wang Y, Chen B, Guo L, Cao L, Ren C, Wen L, Li K, Jia M, Li C, Mok H, Chen X, Wei G, Lin J, Zhang Z, Hou T, Han-Zhang H, Liu C, Liu H, Liu J, Balch CM, Meric-Bernstam F, Liao N. Characterization of frequently mutated cancer genes in Chinese breast tumors: a comparison of Chinese and TCGA cohorts. Ann Transl Med 7(8):179, 2019. e-Pub 2019. PMID: 31168460.
33. Mock C, Debas H, Balch CM, Brennan M, Buyske J, Cusack J, DeMeester S, Herndon D, Le Holterman AX, Jaffe B, Kandil E, Kauffman G, Mazariegos G, sMerchant N, Numann P, Oleynikov D, Olutoye O, O'Neill J, Shackford S, Stock P, Tarpley JL, Tuttle T, Wolf S, Wren SM, Yang GP. Global Surgery: Effective Involvement of US Academic Surgery: Report of the American Surgical Association Working Group on Global Surgery. Ann Surg 268(4):557-563, 2018. e-Pub 2018. PMID: 30004921.
34. Hewitt DB, Merkow RP, DeLancey JO, Wayne JD, Hyngstrom JR, Russell MC, Gerami P, Balch CM, Bilimoria KY. National practice patterns of completion lymph node dissection for sentinel node-positive melanoma. J Surg Oncol 118(3):493-500, 2018. e-Pub 2018. PMID: 30098302.
35. Balch CM. Detection of melanoma metastases with the sentinel node biopsy: the legacy of Donald L. Morton, MD (1934-2014). Clin Exp Metastasis 35(5-6):425-429, 2018. e-Pub 2018. PMID: 29855858.
36. Davis CH, Bass BL, Behrns KE, Lillemoe KD, Garden OJ, Roh MS, Lee JE, Balch CM, Aloia TA. Reviewing the review: a qualitative assessment of the peer review process in surgical journals. Res Integr Peer Rev 3:4, 2018. e-Pub 2018. PMID: 29850109.
37. Balch CM, Klimberg VS, McMasters KM, Pawlik TM, Tanabe KK, Posner MC, Whippen D, Roh MS. Benchmarking the Scientific and Educational Impact of the Annals of Surgical Oncology. Ann Surg Oncol 23(9):223-2729, 2016. e-Pub 2016. PMID: 27334224.
38. Hoekstra HJ, Wobbes T, Heineman E, Haryono S, Aryandono T, Balch CM. Fighting Global Disparities in Cancer Care: A Surgical Oncology View. Ann Surg Oncol 23(7):2131-2136, 2016. e-Pub 2016. PMID: 27038459.
39. Balch JK, Nagy RC, Archibald S, Bowman DM, Moritz MA, Roos CI, Scott AC, Williamson GJ. Global combustion: the connection between fossil fuel and biomass burning emissions (1997-2010). Philos Trans R Soc Lond B Biol Sci 371(1696), 2016. e-Pub 2016. PMID: 27216509.
40. Liao N, Hunt KK, Balch CM. Management of invasive and non-invasive breast cancer in the United States and China. Chin Clin Oncol 5(3):30, 2016. e-Pub 2016. PMID: 27265301.
41. Bao L, Chen M, Shen W, Pan C, Ghiassi KB, Olmstead MM, Balch AL, Akasaka T, Lu X. Regioselective Synthesis and Crystallographic Characterization of Isoxazoline-Ring-Fused Derivatives of Sc3N@Ih-C80 and C60. Inorg Chem 55(9):4075-7, 2016. e-Pub 2016. PMID: 27101430.
42. Constance JE, Balch AH, Stockmann C, Linakis MW, Korgenski EK, Roberts JK, Ward RM, Sherwin CM, Spigarelli MG. A propensity-matched cohort study of vancomycin-associated nephrotoxicity in neonates. Arch Dis Child Fetal Neonatal Ed 101(3):F236-43, 2016. e-Pub 2016. PMID: 26400103.
43. Balch CM, Coit DG, Berman RS. 2015 James Ewing Lecture: 75-Year History of the Society of Surgical Oncology-Part III: The Transformative Years (1991-2015). Ann Surg Oncol 23(5):1409-1417, 2016. e-Pub 2016. PMID: 26822879.
44. Ross MI, Balch CM. Excision Margins of Melanoma Make a Difference: New Data Supports an Old Paradigm. Ann Surg Oncol 23(4):1053-1056, 2016. e-Pub 2016. PMID: 26561402.
45. Balch C, Ogle JD, Senese JL. The National Practice Benchmark for Oncology: 2015 Report for 2014 Data. J Oncol Pract 12(4):e437-75, 2016. e-Pub 2016. PMID: 27006357.
46. Balch AL, Winkler K. Two-Component Polymeric Materials of Fullerenes and the Transition Metal Complexes: A Bridge between Metal-Organic Frameworks and Conducting Polymers. Chem Rev 116(6):3812-82, 2016. e-Pub 2016. PMID: 26900870.
47. Bao L, Chen M, Pan C, Yamaguchi T, Kato T, Olmstead MM, Balch AL, Akasaka T, Lu X. Crystallographic Evidence for Direct Metal-Metal Bonding in a Stable Open-Shell La2 @Ih -C80 Derivative. Angew Chem Int Ed Engl 55(13):4242-6, 2016. e-Pub 2016. PMID: 26918907.
48. Chang HR, Park HS, Ahn YZ, Nam S, Jung HR, Park S, Lee SJ, Balch C, Powis G, Ku JL, Kim YH. Improving gastric cancer preclinical studies using diverse in vitro and in vivo model systems. BMC Cancer 16:200, 2016. e-Pub 2016. PMID: 26955870.
49. Porta C, Allen ML, Hurtado GA, Padilla M, Arboleda M, Svetaz MV, Balch R, Sieving RE. Honoring Roots in Multiple Worlds: Professionals' Perspectives on Healthy Development of Latino Youth. Health Promot Pract 17(2):186-98, 2016. e-Pub 2016. PMID: 26429993.
50. Fenton JJ, Onega T, Zhu W, Balch S, Smith-Bindman R, Henderson L, Sprague BL, Kerlikowske K, Hubbard RA. Validation of a Medicare Claims-based Algorithm for Identifying Breast Cancers Detected at Screening Mammography. Med Care 54(3):e15-22, 2016. e-Pub 2016. PMID: 23929404.
51. Nelson HD, O'Meara ES, Kerlikowske K, Balch S, Miglioretti D. Factors Associated With Rates of False-Positive and False-Negative Results From Digital Mammography Screening: An Analysis of Registry Data. Ann Intern Med 164(4):226-35, 2016. e-Pub 2016. PMID: 26756902.
52. Veit G, Avramescu RG, Chiang AN, Houck SA, Cai Z, Peters KW, Hong JS, Pollard HB, Guggino WB, Balch WE, Skach WR, Cutting GR, Frizzell RA, Sheppard DN, Cyr DM, Sorscher EJ, Brodsky JL, Lukacs GL. From CFTR biology toward combinatorial pharmacotherapy: expanded classification of cystic fibrosis mutations. Mol Biol Cell 27(3):424-33, 2016. e-Pub 2016. PMID: 26823392.
53. Balch CM, Coit DG, Berman RS. 2015 James Ewing Lecture: The 75-Year History of the Society of Surgical Oncology Part II: The Transitional Years (1966-1990). Ann Surg Oncol 23(2):358-64, 2016. e-Pub 2016. PMID: 26464191.
54. Johnson CD, Balch CM. Commentary. Abdom Radiol (NY) 41(2):391, 2016. e-Pub 2016. PMID: 26826085.
55. Cerón MR, Izquierdo M, Alegret N, Valdez JA, Rodríguez-Fortea A, Olmstead MM, Balch AL, Poblet JM, Echegoyen L. Reactivity differences of Sc3N@C(2n) (2n = 68 and 80). Synthesis of the first methanofullerene derivatives of Sc3N@D(5h)-C80. Chem Commun (Camb) 52(1):64-7, 2016. e-Pub 2016. PMID: 26437751.
56. Stevenson S, Arvola KD, Fahim M, Martin BR, Ghiassi KB, Olmstead MM, Balch AL. Isolation and Crystallographic Characterization of Gd3N@D2(35)-C88 through Non-Chromatographic Methods. Inorg Chem 55(1):62-7, 2016. e-Pub 2016. PMID: 26419421.
57. Johnson CD, Balch CM. Editor Note. Ann Surg Oncol. e-Pub 2016. PMID: 26801780.
58. Balch CM, Nelson H, Niederhuber JE. Surgery: Limitations of prospective surgical oncology trials - a US view. Nat Rev Clin Oncol 13(1):6-8, 2016. e-Pub 2016. PMID: 26598945.
59. Balch GC, Bartlett DL. Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The Need for Accessible Data in Real Time. Ann Surg Oncol 23(1):9-11, 2016. e-Pub 2016. PMID: 26265367.
60. Fisher TL, Reilly CA, Winter LA, Pandina T, Jonason A, Scrivens M, Balch L, Bussler H, Torno S, Seils J, Mueller L, Huang H, Klimatcheva E, Howell A, Kirk R, Evans E, Paris M, Leonard JE, Smith ES, Zauderer M. Generation and preclinical characterization of an antibody specific for SEMA4D. MAbs 8(1):150-62, 2016. e-Pub 2016. PMID: 26431358.
61. Balch CM, Coit DG, Berman RS. 2015 James Ewing Lecture: the 75-Year History of the Society of Surgical Oncology - Part II: The Transitional Years (1994-1965). Ann Surg Oncol 23(1):16-22, 2016. e-Pub 2016. PMID: 26340862.
62. Cavanaugh-Hussey MW, Mu EW, Kang S, Balch CM, Wang T. Older Age is Associated with a Higher Incidence of Melanoma Death but a Lower Incidence of Sentinel Lymph Node Metastasis in the SEER Databases (2003-2011). Ann Surg Oncol 22(7):2120-6, 2015. e-Pub 2015. PMID: 25940571.
63. Balch CM, Ross MI. Lymphatic Mapping and the Sentinel Node Biopsy in Melanoma. JAMA Surgery 150(7):623-624, 2015. e-Pub 2015. PMID: 26016730.
64. Balch CM. Decreased survival rates of older-aged patients with melanoma: biological differences under-treatment?. Ann Surg Oncol 22(7):2101-2103, 2015. e-Pub 2015. PMID: 25840561.
65. Balch CM, Thompson JF, Gershenwald JE, Soong SJ, Ding S, McMasters KM, Coit DG, Eggermont AM, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, Ross MI, Byrd DR, Cochran AJ, Mihm MC, Morton DL, Atkins MB, Flaherty KT, Sondak VK. Age as a predictor of sentinel node metastasis among patients with localized melanoma: an inverse correlation of melanoma mortality and incidence of sentinel node metastasis among young and old patients. Ann Surg Oncol 21(4):1075-81, 2014. e-Pub 2014. PMID: 24531700.
66. Klimberg VS, Balch CM. The Distinctive Features of Surgical Oncology as a Specialty. Considerations for Chinese Surgeons. Chinese Clinical Oncology 3(4):44, 2014. e-Pub 2014. PMID: 25841525.
67. Balch CM. The value of multidisciplinary cancer care and research: the role of the surgeon as an oncologists and clinical investigator. Chinese Clinical Oncology 3(4):42, 2014. e-Pub 2014. PMID: 25841523.
68. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Coit DG, Atkins MB, Ding S, Cochran AJ, Eggermont AM, Flaherty KT, Gimotty PA, Johnson TM, Kirkwood JM, Leong SP, McMasters KM, Mihm MC, Morton DL, Ross MI, Sondak VK. Age as a prognostic factor in patients with localized melanoma and regional metastases. Ann Surg Oncol 20(12):3961-8, 2013. e-Pub 2013. PMID: 23838920.
69. Dyrbye LN, Freischlag J, Kaups KL, Oreskovich MR, Satele DV, Hanks JB, Sloan JA, Balch CM, Shanafelt TD. Work-home conflicts have a substantial impact on career decisions that affect the adequacy of the surgical workforce. Arch Surg 147(10):933-9, 2012. e-Pub 2012. PMID: 23117833.
70. Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, Cochran A, Cormier JN, Gorman M, Kim TY, McMasters KM, Noyes RD, Schuchter LM, Valsecchi ME, Weaver DL, Lyman GH, Clinical Oncology ASO, Surgical Oncology SO. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. Ann Surg Oncol 19(11):3313-24, 2012. e-Pub 2012. PMID: 22766987.
71. Shanafelt TD, Oreskovich MR, Dyrbye LN, Satele DV, Hanks JB, Sloan JA, Balch CM. Avoiding burnout: the personal health habits and wellness practices of US surgeons. Ann Surg 255(4):625-33, 2012. e-Pub 2012. PMID: 22388107.
72. Oreskovich MR, Kaups KL, Balch CM, Hanks JB, Satele D, Sloan J, Meredith C, Buhl A, Dyrbye LN, Shanafelt TD. Prevalence of alcohol use disorders among American surgeons. Arch Surg 147(2):168-74, 2012. e-Pub 2012. PMID: 22351913.
73. Balch CM. The importance of surgical oncology in China: a view from across the ocean. Chinese Clinical Oncology 1(2):16, 2012. e-Pub 2012.
74. Bilimoria KY, Raval MV, Bentrem DJ, Wayne JD, Balch CM, Ko CY. National assessment of melanoma care using formally developed quality indicators. J Clin Oncol 27(32):5445-51, 2009. e-Pub 2009. PMID: 19826131.
75. Shanafelt TD, Balch CM, Bechamps GJ, Russell T, Dyrbye L, Satele D, Collicott P, Novotny PJ, Sloan J, Freischlag JA. Burnout and career satisfaction among American surgeons. Ann Surg 250(3):463-71, 2009. e-Pub 2009. PMID: 19730177.
76. Ding S, Soong SJ, Lin HY, Desmond R, Balch CM. Parametric modeling of localized melanoma prognosis and outcome. J Biopharm Stat 19(4):732-47, 2009. e-Pub 2009. PMID: 20183437.
77. Balch CM, Morton DL, Gershenwald JE, McMasters KM, Nieweg OE, Powell B, Ross MI, Sondak VK, Thompson JF. Sentinel node biopsy and standard of care for melanoma. J Am Acad Dermatol 60(5):872-5, 2009. e-Pub 2009. PMID: 19389531.
78. Bilimoria KY, Balch CM, Wayne JD, Chang DC, Palis BE, Dy SM, Lange JR. Health care system and socioeconomic factors associated with variance in use of sentinel lymph node biopsy for melanoma in the United States. J Clin Oncol 27(11):1857-63, 2009. e-Pub 2009. PMID: 19273706.
79. Voltura AM, Tsangaris TN, Rosson GD, Jacobs LK, Flores JI, Singh NK, Argani P, Balch CM. Nipple-sparing mastectomy: critical assessment of 51 procedures and implications for selection criteria. Ann Surg Oncol 15(12):3396-401, 2008. e-Pub 2008. PMID: 18923874.
80. Bilimoria KY, Balch CM, Bentrem DJ, Talamonti MS, Ko CY, Lange JR, Winchester DP, Wayne JD. Complete lymph node dissection for sentinel node-positive melanoma: assessment of practice patterns in the United States. Ann Surg Oncol 15(6):1566-76, 2008. e-Pub 2008. PMID: 18414952.
81. Cao D, Tsangaris TN, Kouprina N, Wu LS, Balch CM, Vang R, Argani P. The superficial margin of the skin-sparing mastectomy for breast carcinoma: factors predicting involvement and efficacy of additional margin sampling. Ann Surg Oncol 15(5):1330-40, 2008. e-Pub 2008. PMID: 18246402.
82. Balch CM, Copeland E. Stress and burnout among surgical oncologists: a call for personal wellness and a supportive workplace environment. Ann Surg Oncol 14(11):3029-32, 2007. e-Pub 2007. PMID: 17899284.
83. Cummins DL, Esche C, Barrett TL, Balch CM, Mofid M. Lymph node biopsy results for desmoplastic malignant melanoma. Cutis 79(5):390-4, 2007. e-Pub 2007. PMID: 17569403.
84. Lange JR, Palis BE, Chang DC, Soong SJ, Balch CM. Melanoma in children and teenagers: an analysis of patients from the National Cancer Data Base. J Clin Oncol 25(11):1363-8, 2007. e-Pub 2007. PMID: 17416855.
85. Tsai CA, Chen DT, Chen JJ, Balch CM, Thompson JF, Soong SJ. An integrated tree-based classification approach to prognostic grouping with application to localized melanoma patients. J Biopharm Stat 17(3):445-60, 2007. e-Pub 2007. PMID: 17479393.
86. Krueger GM, Alexander LL, Whippen DA, Balch CM. Arnoldus Goudsmit, MD, PhD: chemotherapist, visionary, founder of the American Society of Clinical Oncology, 1909-2005. J Clin Oncol 24(24):4033-6, 2006. e-Pub 2006. PMID: 16921061.
87. Lange JR, Balch CM. Melanoma in children: heightened awareness of an uncommon but often curable malignancy. Pediatrics 115(3):802-3, 2005. e-Pub 2005. PMID: 15741391.
88. Dessureault S, Soong SJ, Ross MI, Thompson JF, Kirkwood JM, Gershenwald JE, Coit DG, McMasters KM, Balch CM, Reintgen D, Staging Committee AJCOCM. Improved staging of node-negative patients with intermediate to thick melanomas (>1 mm) with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol 8(10):766-70, 2001. e-Pub 2001. PMID: 11776489.
89. Balch CM, Soong SJ, Gershenwald JE, Thompson JF, Reintgen DS, Cascinelli N, Urist M, McMasters KM, Ross MI, Kirkwood JM, Atkins MB, Thompson JA, Coit DG, Byrd D, Desmond R, Zhang Y, Liu PY, Lyman GH, Morabito A. Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol 19(16):3622-34, 2001. e-Pub 2001. PMID: 11504744.
90. Balch CM, Cascinelli N. The new melanoma staging system. Tumori 87(4):S64-8, 2001. e-Pub 2001. PMID: 11693828.
91. Gutman H, Hess KR, Kokotsakis JA, Ross MI, Guinee VF, Balch CM. Surgery for abdominal metastases of cutaneous melanoma. World J Surg 25(6):750-8, 2001. e-Pub 2001. PMID: 11376411.
92. Balch CM, Soong SJ, Smith T, Ross MI, Urist MM, Karakousis CP, Temple WJ, Mihm MC, Barnhill RL, Jewell WR, Wanebo HJ, Desmond R, Surgical Trial IFTIM. Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann Surg Oncol 8(2):101-8, 2001. e-Pub 2001. PMID: 11258773.
93. Slominski A, Wortsman J, Carlson AJ, Matsuoka LY, Balch CM, Mihm MC. Malignant Melanoma. Arch Pathol Lab MEd 125:1295-1306, 2001. e-Pub 2001.
94. Balch CM, Buzaid AC, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Houghton A, Kirkwood JM, Mihm MF, Morton DL, Reintgen D, Ross MI, Sober A, Soong SJ, Thompson JA, Thompson JF, Gershenwald JE, McMasters KM. A new American Joint Committee on Cancer staging system for cutaneous melanoma. Cancer 88(6):1484-91, 2000. e-Pub 2000. PMID: 10717634.
95. Balch CM, Soong S, Ross MI, Urist MM, Karakousis CP, Temple WJ, Mihm MC, Barnhill RL, Jewell WR, Wanebo HJ, Harrison R. Long-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical Trial. Ann Surg Oncol 7(2):87-97, 2000. e-Pub 2000. PMID: 10761786.
96. Schwarz RE, Chow WA, Andersen JS, Arber DA, Balch CM. Soft tissue masses of the chest wall and axilla: has metastatic melanoma been considered?. Am J Clin Oncol 22(2):174-7, 1999. e-Pub 1999. PMID: 10199454.
97. Gershenwald JE, Thompson W, Mansfield PF, Lee JE, Colome MI, Tseng CH, Lee JJ, Balch CM, Reintgen DS, Ross MI. Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients. J Clin Oncol 17(3):976-83, 1999. e-Pub 1999. PMID: 10071292.
98. Karakousis CP, Balch CM, Bartolucci A, Driscoll DL. Is the capacity for lymph node-mediated distant dissemination the same for all nodal groups in malignant melanoma?. Melanoma Res 8(5):419-24, 1998. e-Pub 1998. PMID: 9835455.
99. Talley LI, Soong S, Harrison RA, McCarthy WH, Urist MM, Balch CM. Clinical outcomes of localized melanoma of the foot: a case-control study. J Clin Epidemiol 51(10):853-7, 1998. e-Pub 1998. PMID: 9762878.
100. Bold RJ, Mansfield PF, Berger DH, Pollock RE, Singletary SE, Ames FC, Balch CM, Hohn DC, Ross MI. Prospective, randomized, double-blind study of prophylactic antibiotics in axillary lymph node dissection. Am J Surg 176(3):239-43, 1998. e-Pub 1998. PMID: 9776150.
101. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty L, Richards JM, Bartolucci AA, Rosen L. Surgical adjuvant active specific immunotherapy for patients with stage III melanoma: the final analysis of data from a phase III, randomized, double-blind, multicenter vaccinia melanoma oncolysate trial. J Am Coll Surg 187(1):69-77; discussion 77-9, 1998. e-Pub 1998. PMID: 9660028.
102. Balch CM. The John Wayne Clinical Research Lecture. Surgical management of melanoma: results of prospective randomized trials. Ann Surg Oncol 5(4):301-9, 1998. e-Pub 1998. PMID: 9641450.
103. Gershenwald JE, Colome MI, Lee JE, Mansfield PF, Tseng C, Lee JJ, Balch CM, Ross MI. Patterns of recurrence following a negative sentinel lymph node biopsy in 243 patients with stage I or II melanoma. J Clin Oncol 16(6):2253-60, 1998. e-Pub 1998. PMID: 9626228.
104. Soong SJ, Harrison RA, McCarthy WH, Urist MM, Balch CM. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 67(4):228-33, 1998. e-Pub 1998. PMID: 9579369.
105. Eton O, Legha SS, Moon TE, Buzaid AC, Papadopoulos NE, Plager C, Burgess AM, Bedikian AY, Ring S, Dong Q, Glassman AB, Balch CM, Benjamin RS. Prognostic factors for survival of patients treated systemically for disseminated melanoma. J Clin Oncol 16(3):1103-11, 1998. e-Pub 1998. PMID: 9508197.
106. Eton O, Kharkevitch DD, Gianan MA, Ross MI, Itoh K, Pride MW, Donawho C, Buzaid AC, Mansfield PF, Lee JE, Legha SS, Plager C, Papadopoulos NE, Bedikian AY, Benjamin RS, Balch CM. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma. Clin Cancer Res 4(3):619-27, 1998. e-Pub 1998. PMID: 9533529.
107. Wallack MK, Sivanandham M, Ditaranto K, Shaw P, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty L, Richards JM, Rosen L, Bartolucci AA. Increased survival of patients treated with a vaccinia melanoma oncolysate vaccine: second interim analysis of data from a phase III, multi-institutional trial. Ann Surg 226(2):198-206, 1997. e-Pub 1997. PMID: 9296514.
108. Huang X, Soong S, McCarthy WH, Urist MM, Balch CM. Classification of localized melanoma by the exponential survival trees method. Cancer 79(6):1122-8, 1997. e-Pub 1997. PMID: 9070489.
109. Buzaid AC, Ross MI, Balch CM, Soong S, McCarthy WH, Tinoco L, Mansfield P, Lee JE, Bedikian A, Eton O, Plager C, Papadopoulos N, Legha SS, Benjamin RS. Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. J Clin Oncol 15(3):1039-51, 1997. e-Pub 1997. PMID: 9060544.
110. Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial. Ann Surg Oncol 3(5):446-52, 1996. e-Pub 1996. PMID: 8876886.
111. Balch CM, Soong SJ, Bartolucci AA, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Ross MI, Jewell WR, Mihm MC, Barnhill RL, Wanebo HJ. Efficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and younger. Ann Surg 224(3):255-63; discussion 263-6, 1996. e-Pub 1996. PMID: 8813254.
112. McKneally MF, Gleeson S, Balch CM, Mussallem MA, Abel DB, Bernhard VM. Can surgical innovation survive? Panel presentations. Bull Am Coll Surg 81(4):8-21, 43, 1996. e-Pub 1996. PMID: 10156765.
113. Skibber JM, Soong SJ, Austin L, Balch CM, Sawaya RE. Cranial irradiation after surgical excision of brain metastases in melanoma patients. Ann Surg Oncol 3(2):118-23, 1996. e-Pub 1996. PMID: 8646510.
114. El-Naggar AK, Kemp BL, Sneige N, Hurr KG, Steck K, Tu ZN, Fritsche HA, Singletary SE, Balch CM. Bivariate RNA and DNA content analysis in breast carcinoma: biological significance of RNA content. Clin Cancer Res 2(2):419-26, 1996. e-Pub 1996. PMID: 9816186.
115. McKneally MF, Gleeson S, Balch CM, Mussallem MA, Abel DB, Bernhard VM. Can surgical innovation survive? Panel presentations. Bull Am Coll Surg 81:8-21, 1996. e-Pub 1996.
116. Buzaid AC, Tinoco LA, Jendiroba D, Tu ZN, Lee JJ, Legha SS, Ross MI, Balch CM, Benjamin RS. Prognostic value of size of lymph node metastases in patients with cutaneous melanoma. J Clin Oncol 13(9):2361-8, 1995. e-Pub 1995. PMID: 7666095.
117. Wallack MK, Sivanandham M, Balch CM, Urist MM, Bland KI, Murray D, Robinson WA, Flaherty LE, Richards JM, Bartolucci AA. A phase III randomized, double-blind multiinstitutional trial of vaccinia melanoma oncolysate-active specific immunotherapy for patients with stage II melanoma. Cancer 75(1):34-42, 1995. e-Pub 1995. PMID: 7804974.
118. Risin D, Kleinerman ES, Umezu Y, Pizzini RP, Balch CM, Pellis NR. Impairment of lymphocyte locomotion in the tumor microenvironment and the effect of systemic immunotherapy with liposome-encapsulated muramyl-tripeptide-phosphatidylethanolamine. Cancer Immunol Immunother 40(1):57-64, 1995. e-Pub 1995. PMID: 7828168.
119. Buzaid A, Legha SS, Balch CM, Ross M, Ring S, Plager C, Papadopoulos NE, el-Naggar AK, Benjamin RS. Pilot study of preoperative chemotherapy with cisplatin, vinblastine, and dacarbazine in patients with local-regional recurrence of melanoma. Cancer 74(9):2476-82, 1994. e-Pub 1994. PMID: 7923003.
120. Kharkevitch DD, Seito D, Balch GC, Maeda T, Balch CM, Itoh K. Characterization of autologous tumor-specific T-helper 2 cells in tumor-infiltrating lymphocytes from a patient with metastatic melanoma. Int J Cancer 58(3):317-23, 1994. e-Pub 1994. PMID: 7914181.
121. Heaton KM, el-Naggar A, Ensign LG, Ross MI, Balch CM. Surgical management and prognostic factors in patients with subungual melanoma. Ann Surg 219(2):197-204, 1994. e-Pub 1994. PMID: 8129491.
122. Heaton KM, Rippon MB, el-Naggar A, Tucker SL, Ross MI, Balch CM. Prognostic implications of DNA index in patients with stage III cutaneous melanoma. Am J Surg 166(6):648-52; discussion 652-3, 1993. e-Pub 1993. PMID: 8273843.
123. Miller MJ, Balch CM. "Iris" technique for immediate umbilical reconstruction. Plast Reconstr Surg 92(4):754-6, 1993. e-Pub 1993. PMID: 8356139.
124. Balch CM, Urist MM, Karakousis CP, Smith TJ, Temple WJ, Drzewiecki K, Jewell WR, Bartolucci AA, Mihm MC, Barnhill R. Efficacy of 2-cm surgical margins for intermediate-thickness melanomas (1 to 4 mm). Results of a multi-institutional randomized surgical trial. Ann Surg 218(3):262-7; discussion 267-9, 1993. e-Pub 1993. PMID: 8373269.
125. Schusterman MA, Kroll SS, Reece GP, Miller MJ, Ainslie N, Halabi S, Balch CM. Incidence of autoimmune disease in patients after breast reconstruction with silicone gel implants versus autogenous tissue: a preliminary report. Ann Plast Surg 31(1):1-6, 1993. e-Pub 1993. PMID: 8395164.
126. Fujimaki W, Itoh K, An T, Gano JB, Ross MI, Mansfield PF, Balch CM, Augustus LB, Karkevitch DD, Johnston D. Cytokine production and immune cell activation in melanoma patients treated with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Biother 8(4):307-18, 1993. e-Pub 1993. PMID: 7804372.
127. Balch CM. Surgical oncology in the 21st century. Arch Surg 127(11):1272-7, 1992. e-Pub 1992. PMID: 1444785.
128. Balch CM. Cutaneous melanoma: prognosis and treatment results worldwide. Semin Surg Oncol 8(6):400-14, 1992. e-Pub 1992. PMID: 1439450.
129. Itoh K, Salmeron MA, Morita T, Seito D, Mansfield PF, Ross MI, Balch CM, Augustus LB. Distribution of autologous tumor-specific cytotoxic T lymphocytes in human metastatic melanoma. Int J Cancer 52(1):52-9, 1992. e-Pub 1992. PMID: 1500228.
130. Voravud N, el-Naggar AK, Balch CM, Theriault RL. Metastatic lobular breast carcinoma simulating primary colon cancer. Am J Clin Oncol 15(4):365-9, 1992. e-Pub 1992. PMID: 1514536.
131. Salmeron MA, Balch CM, Ross MI, Itoh K. Role of uncultured human melanoma cells in the proliferation of autologous tumor-specific cytotoxic T lymphocytes. Cell Immunol 143(1):228-37, 1992. e-Pub 1992. PMID: 1623565.
132. Soong SJ, Shaw HM, Balch CM, McCarthy WH, Urist MM, Lee JY. Predicting survival and recurrence in localized melanoma: a multivariate approach. World J Surg 16(2):191-5, 1992. e-Pub 1992. PMID: 1561798.
133. Itoh K, Balch CM, Murray JL, Parkinson DR, Markowitz AB, Talpaz M, Lee K, Zukiwski AA, Ross MI, Legha SS. Immunological properties of melanoma tumor-infiltrating lymphocytes before and after IL-2-based biotherapies. In Vivo 5(6):647-53, 1991. e-Pub 1991. PMID: 1810451.
134. Hayakawa K, Salmeron MA, Parkinson DR, Markowitz AB, von Eschenbach AC, Legha SS, Balch CM, Ross MI, Augustus LB, Itoh K. Study of tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma (RCC) and metastatic melanoma: sequential proliferation of cytotoxic natural killer and noncytotoxic T cells in RCC. J Immunother (1991) 10(5):313-25, 1991. e-Pub 1991. PMID: 1790139.
135. Lipton A, Harvey HA, Balch CM, Antle CE, Heckard R, Bartolucci AA. Corynebacterium parvum versus bacille Calmette-Guérin adjuvant immunotherapy of stage II malignant melanoma. J Clin Oncol 9(7):1151-6, 1991. e-Pub 1991. PMID: 2045856.
136. Broadwater JR, Edwards MJ, Kuglen C, Hortobagyi GN, Ames FC, Balch CM. Mastectomy following preoperative chemotherapy. Strict operative criteria control operative morbidity. Ann Surg 213(2):126-9, 1991. e-Pub 1991. PMID: 1992938.
137. Itoh K, Hayakawa K, Salmeron MA, Legha SS, Murray JL, Talpaz M, Balch CM, Parkinson DR, Lee K, Zukiwski AA. Alteration in interactions between tumor-infiltrating lymphocytes and tumor cells in human melanomas after chemotherapy or immunotherapy. Cancer Immunol Immunother 33(4):238-46, 1991. e-Pub 1991. PMID: 2059968.
138. Applegate KG, Balch CM, Pellis NR. In vitro migration of lymphocytes through collagen matrix: arrested locomotion in tumor-infiltrating lymphocytes. Cancer Res 50(22):7153-8, 1990. e-Pub 1990. PMID: 2224850.
139. Riley LB, Pellis NR, Schantz SP, Freedman RS, Balch CM, Itoh K. Humoral modulation of lymphokine-activated killer (LAK)-cell induction in humans: IgG-related and non-IgG inhibitors in sera from cancer patients. Int J Cancer 46(5):785-91, 1990. e-Pub 1990. PMID: 2228306.
140. Kim TY, von Eschenbach AC, Filaccio MD, Hayakawa K, Parkinson DR, Balch CM, Itoh K. Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma. Cancer Res 50(17):5263-8, 1990. e-Pub 1990. PMID: 2143685.
141. Stotter A, Atkinson EN, Fairston BA, McNeese M, Oswald MJ, Balch CM. Survival following locoregional recurrence after breast conservation therapy for cancer. Ann Surg 212(2):166-72, 1990. e-Pub 1990. PMID: 2198001.
142. Balch CM. Excising melanomas: how wide is enough? And how to reconstruct?. J Surg Oncol 44(3):135-7, 1990. e-Pub 1990. PMID: 2370796.
143. Balch CM. Axillary lymph node dissection: differences in goals and techniques when treating melanoma and breast cancer. Surgery 108(1):118-9, 1990. e-Pub 1990. PMID: 2360181.
144. Edwards MJ, Soong SJ, Boddie AW, Balch CM, McBride CM. Isolated limb perfusion for localized melanoma of the extremity. A matched comparison of wide local excision with isolated limb perfusion and wide local excision alone. Arch Surg 125(3):317-21, 1990. e-Pub 1990. PMID: 2306179.
145. Balch CM. The surgeon's expanded role in cancer care. Cancer 65(3 Suppl):604-9, 1990. e-Pub 1990. PMID: 1689207.
146. Balch CM, Riley LB, Bae YJ, Salmeron MA, Platsoucas CD, von Eschenbach A, Itoh K. Patterns of human tumor-infiltrating lymphocytes in 120 human cancers. Arch Surg 125(2):200-5, 1990. e-Pub 1990. PMID: 1689143.
147. Calabro A, Singletary SE, Balch CM. Patterns of relapse in 1001 consecutive patients with melanoma nodal metastases. Arch Surg 124(9):1051-5, 1989. e-Pub 1989. PMID: 2774907.
148. McCready DR, Balch CM, Fidler IJ, Murray JL. Lack of comparability between binding of monoclonal antibodies to melanoma cells in vitro and localization in vivo. J Natl Cancer Inst 81(9):682-7, 1989. e-Pub 1989. PMID: 2709424.
149. Yagita M, Itoh K, Tsudo M, Schaub LB, Platsoucas CD, Balch CM, Grimm EA. Involvement of both Tac and non-Tac interleukin 2-binding peptides in the interleukin 2-dependent proliferation of human tumor-infiltrating lymphocytes. Cancer Res 49(5):1154-9, 1989. e-Pub 1989. PMID: 2783885.
150. McCready DR, Hortobagyi GN, Kau SW, Smith TL, Buzdar AU, Balch CM. The prognostic significance of lymph node metastases after preoperative chemotherapy for locally advanced breast cancer. Arch Surg 124(1):21-5, 1989. e-Pub 1989. PMID: 2910244.
151. Pollock RE, Balch CM. The NIH clinician-investigator award: how to write a training grant application. J Surg Res 46(1):1-3, 1989. e-Pub 1989. PMID: 2915532.
152. McCready DR, Price J, Balch CM, Murray JL. Altered biodistribution of indium-111-labeled monoclonal antibody 96.5 to tumors and normal tissues of nude mice bearing human melanoma xenografts in visceral organs. Cancer Immunol Immunother 30(5):257-61, 1989. e-Pub 1989. PMID: 2624918.
153. Itoh K, Pellis NR, Balch CM. Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients. Cancer Immunol Immunother 29(1):57-62, 1989. e-Pub 1989. PMID: 2785000.
154. Boddie AW, Balch CM. Three unresolved issues in the surgical treatment of melanoma. Oncology (Williston Park) 2(11):39-44, 48-50, 1988. e-Pub 1988. PMID: 3275043.
155. Itoh K, Platsoucas CD, Balch CM. Autologous tumor-specific cytotoxic T lymphocytes in the infiltrate of human metastatic melanomas. Activation by interleukin 2 and autologous tumor cells, and involvement of the T cell receptor. J Exp Med 168(4):1419-41, 1988. e-Pub 1988. PMID: 3262710.
156. Edwards MJ, Broadwater JR, Bell JL, Ames FC, Balch CM. Economic impact of reducing hospitalization for mastectomy patients. Ann Surg 208(3):330-6, 1988. e-Pub 1988. PMID: 3421757.
157. Itoh K, Balch CM, Platsoucas CD. Monocyte-independent interleukin-2 production and proliferation of human T cells in response to murine hybridomas expressing the OKT3 monoclonal antibody: interleukin-1 is not required for T-cell proliferation. Cell Immunol 115(1):36-56, 1988. e-Pub 1988. PMID: 2969776.
158. Itoh K, Balch CM, Trial J, Platsoucas CD. CD8+ T cells lyse autologous monocytes in the presence of anti-CD3 monoclonal antibody: association with interleukin-1 production. Cell Immunol 114(2):257-71, 1988. e-Pub 1988. PMID: 3260540.
159. Han X, Itoh K, Balch CM, Pellis NR. Recombinant interleukin 4 (RIL4) inhibits interleukin 2-induced activation of peripheral blood lymphocytes. Lymphokine Res 7(3):227-35, 1988. e-Pub 1988. PMID: 3263554.
160. Maddox WA, Carpenter JT, Laws HT, Soong SJ, Cloud G, Balch CM, Urist MM. Does radical mastectomy still have a place in the treatment of primary operable breast cancer?. Arch Surg 122(11):1317-20, 1987. e-Pub 1987. PMID: 2823746.
161. Itoh K, Platsoucas CD, Tilden AB, Pollock RE, Balch CM. Lysis of fresh solid tumor targets in the presence of Con A is mediated primarily by Leu 7+ peripheral blood T lymphocytes: blocking by the anti-CD3 monoclonal antibody and comparison with recombinant interleukin 2-induced lysis by natural killer cells. Cell Immunol 108(2):283-96, 1987. e-Pub 1987. PMID: 3113741.
162. Itoh K, Balch CM, Platsoucas CD. Spontaneous human T-cell cytotoxicity against murine hybridomas expressing the OKT3 monoclonal antibody: comparison with natural killer cell activity. Cell Immunol 108(2):313-22, 1987. e-Pub 1987. PMID: 3113742.
163. Itoh K, Platsoucas CD, Balch CM. Monocyte- and natural killer cell-mediated spontaneous cytotoxicity against human noncultured solid tumor cells. Cell Immunol 108(2):495-500, 1987. e-Pub 1987. PMID: 3113744.
164. Balch CM, Levin B. Regional and systemic chemotherapy for colorectal metastases to the liver. World J Surg 11(4):521-6, 1987. e-Pub 1987. PMID: 2957860.
165. Fidler IJ, Balch CM. The biology of cancer metastasis and implications for therapy. Curr Probl Surg 24(3):129-209, 1987. e-Pub 1987. PMID: 3568753.
166. Tilden AB, Itoh K, Balch CM. Human lymphokine-activated killer (LAK) cells: identification of two types of effector cells. J Immunol 138(4):1068-73, 1987. e-Pub 1987. PMID: 3100627.
167. Balch CM, Soong SJ, Shaw HM. [Malignant melanoma--compared worldwide]. Chirurg 57(10):601-5, 1986. e-Pub 1986. PMID: 3491743.
168. Balch CM. Immune responses to tumor antigens and their clinical applications. Surgery 100(3):562-71, 1986. e-Pub 1986. PMID: 3488601.
169. Wornom IL, Smith JW, Soong SJ, McElvein R, Urist MM, Balch CM. Surgery as palliative treatment for distant metastases of melanoma. Ann Surg 204(2):181-5, 1986. e-Pub 1986. PMID: 2427043.
170. Tilden AB, Cauda R, Grossi CE, Balch CM, Lakeman AD, Whitley RJ. Demonstration of NK cell-mediated lysis of varicella-zoster virus (VZV)-infected cells: characterization of the effector cells. J Immunol 136(11):4243-8, 1986. e-Pub 1986. PMID: 3009620.
171. Itoh K, Tilden AB, Balch CM. Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res 46(6):3011-7, 1986. e-Pub 1986. PMID: 3486040.
172. Itoh K, Tilden AB, Balch CM. Lysis of human solid tumor cells by lymphokine-activated natural killer cells. J Immunol 136(10):3910-5, 1986. e-Pub 1986. PMID: 3084648.
173. Balch CM. The academic surgeon as a clinical investigator. J Surg Res 40(5):413-20, 1986. e-Pub 1986. PMID: 3525989.
174. Tilden AB, Grossi CE, Itoh K, Cloud GA, Dougherty PA, Balch CM. Subpopulation analysis of human granular lymphocytes: associations with age, gender and cytotoxic activity. Nat Immun Cell Growth Regul 5(2):90-9, 1986. e-Pub 1986. PMID: 3724768.
175. Balch CM, Urist MM. Intraarterial chemotherapy for colorectal liver metastases and hepatomas using a totally implantable drug infusion pump. Recent Results Cancer Res 100:234-47, 1986. e-Pub 1986. PMID: 3016842.
176. Balch CM. [Therapy of malignant melanoma]. Dtsch Med Wochenschr 110(46):1786-91, 1985. e-Pub 1985. PMID: 4054006.
177. Abo T, Landay A, Balch CM, Cooper MD. A human B cell differentiation antigen selectively expressed on mature B cells identified by a monoclonal antibody (HB-2). Hum Immunol 13(4):253-64, 1985. e-Pub 1985. PMID: 3928543.
178. Balch CM, Itoh K, Tilden AB. Cellular immune defects in patients with melanoma involving interleukin-2-activated lymphocyte cytotoxicity and a serum suppressor factor. Surgery 98(2):151-7, 1985. e-Pub 1985. PMID: 3875156.
179. Itoh K, Tilden AB, Balch CM. Role of interleukin 2 and a serum suppressive factor on the induction of activated killer cells cytotoxic for autologous human melanoma cells. Cancer Res 45(7):3173-8, 1985. e-Pub 1985. PMID: 3924397.
180. Shaw HM, Balch CM, Soong SJ, Milton GW, McCarthy WH. Prognostic histopathological factors in malignant melanoma. Pathology 17(2):271-4, 1985. e-Pub 1985. PMID: 4047730.
181. Trotter MC, Cloud GA, Davis M, Sanford SP, Urist MM, Soong SJ, Halpern NB, Maddox WA, Balch CM. Predicting the risk of abdominal disease in Hodgkin's lymphoma. A multifactorial analysis of staging laparotomy results in 255 patients. Ann Surg 201(4):465-9, 1985. e-Pub 1985. PMID: 3977447.
182. Rubin E, Balch CM. Breast cancer. Diagnosis and treatment. Ala J Med Sci 22(2):215-22, 1985. e-Pub 1985. PMID: 4003706.
183. Urist MM, Balch CM, Soong S, Shaw HM, Milton GW, Maddox WA. The influence of surgical margins and prognostic factors predicting the risk of local recurrence in 3445 patients with primary cutaneous melanoma. Cancer 55(6):1398-402, 1985. e-Pub 1985. PMID: 3971310.
184. Itoh K, Tilden AB, Kumagai K, Balch CM. Leu-11+ lymphocytes with natural killer (NK) activity are precursors of recombinant interleukin 2 (rIL 2)-induced activated killer (AK) cells. J Immunol 134(2):802-7, 1985. e-Pub 1985. PMID: 3917475.
185. Ziegler-Heitbrock HW, Rumpold H, Kraft D, Wagenpfeil C, Munker R, Abo T, Balch CM, LeBien TW. Patients with a deficiency of natural killer cell activity lack the VEP13-positive lymphocyte subpopulation. Blood 65(1):65-70, 1985. e-Pub 1985. PMID: 3965053.
186. Urist MM, Balch CM, Soong SJ, Milton GW, Shaw HM, McGovern VJ, Murad TM, McCarthy WH, Maddox WA. Head and neck melanoma in 534 clinical Stage I patients. A prognostic factors analysis and results of surgical treatment. Ann Surg 200(6):769-75, 1984. e-Pub 1984. PMID: 6508408.
187. Marolda R, Tilden AB, Abo T, Dougherty PA, Balch CM. Characterization of a subset of human natural killer cells that express OKM1 but lack HNK-1 (Leu-7) antigens. Scand J Immunol 20(3):261-5, 1984. e-Pub 1984. PMID: 6238402.
188. Balch CM, Urist MM. [Intra-arterial chemotherapy using an implantable infusion pump in liver metastases of colorectal tumors and hepatomas]. Chirurg 55(8):485-93, 1984. e-Pub 1984. PMID: 6092009.
189. AboT, Tilden AB, Balch CM, Kumagai K, Troup GM, Cooper MD. Ethnic differences in the lymphocyte proliferative response induced by a murine IgG1 antibody, Leu-4, to the T3 molecule. J Exp Med 160(1):303-9, 1984. e-Pub 1984. PMID: 6429266.
190. Abo T, Miller CA, Balch CM. Characterization of human granular lymphocyte subpopulations expressing HNK-1 (Leu-7) and Leu-11 antigens in the blood and lymphoid tissues from fetuses, neonates and adults. Eur J Immunol 14(7):616-23, 1984. e-Pub 1984. PMID: 6430709.
191. James SP, Neckers LM, Graeff AS, Cossman J, Balch CM, Strober W. Suppression of immunoglobulin synthesis by lymphocyte subpopulations in patients with Crohn's disease. Gastroenterology 86(6):1510-8, 1984. e-Pub 1984. PMID: 6232165.
192. Denton JW, Dunham WK, Salter M, Urist MM, Balch CM. Preoperative regional chemotherapy and rapid-fraction irradiation for sarcomas of the soft tissue and bone. Surg Gynecol Obstet 158(6):545-51, 1984. e-Pub 1984. PMID: 6587604.
193. Bonewald L, Wang AC, Wang IY, Balch CM, Ades EW. Antigenic determinant(s) shared by the human Thy 1 and human IgG. Immunobiology 166(4-5):428-38, 1984. e-Pub 1984. PMID: 6207102.
194. Balch CM, Durant JR, Bartolucci AA. The impact of surgical quality control in multi-institutional group trials involving adjuvant cancer treatments. Ann Surg 198(2):164-7, 1983. e-Pub 1983. PMID: 6347102.
195. Balch CM, Tilden AB, Dougherty PA, Cloud GA. Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients. Ann Surg 198(2):192-9, 1983. e-Pub 1983. PMID: 6870377.
196. Balch CM, Urist MM. [Completely implantable infusion pump. A new therapeutic possibility for selected patients with liver tumors]. Dtsch Med Wochenschr 108(26):1008-13, 1983. e-Pub 1983. PMID: 6303741.
197. Urist MM, Maddox WA, Kennedy JE, Balch CM. Patient risk factors and surgical morbidity after regional lymphadenectomy in 204 melanoma patients. Cancer 51(11):2152-6, 1983. e-Pub 1983. PMID: 6839303.
198. Abo T, Balch CM. In vitro propagation of cultured human natural killer cells expressing the HNK-1 differentiation antigen and spontaneous cytotoxic function. Eur J Immunol 13(5):383-9, 1983. e-Pub 1983. PMID: 6406236.
199. Egan ML, Mendelsohn SL, Abo T, Balch CM. Natural killer cells in systemic lupus erythematosus. Abnormal numbers and functional immaturity of HNK-1+ cells. Arthritis Rheum 26(5):623-9, 1983. e-Pub 1983. PMID: 6687804.
200. Sack J, Urist MM, Balch CM, Aldrete JS. Hepatocellular carcinoma: characteristics and current management. Ala J Med Sci 20(2):182-5, 1983. e-Pub 1983. PMID: 6305227.
201. Tilden AB, Abo T, Balch CM. Suppressor cell function of human granular lymphocytes identified by the HNK-1 (Leu 7) monoclonal antibody. J Immunol 130(3):1171-5, 1983. e-Pub 1983. PMID: 6218202.
202. Balch CM, Urist MM, McGregor ML. Continuous regional chemotherapy for metastatic colorectal cancer using a totally implantable infusion pump. A feasibility study in 50 patients. Am J Surg 145(2):285-90, 1983. e-Pub 1983. PMID: 6218762.
203. Balch CM, Soong SJ, Murad TM, Smith JW, Maddox WA, Durant JR. A multifactorial analysis of melanoma. IV. Prognostic factors in 200 melanoma patients with distant metastases (stage III). J Clin Oncol 1(2):126-34, 1983. e-Pub 1983. PMID: 6668496.
204. Richards PC, Balch CM, Aldrete JS. Abdominal wound closure. A randomized prospective study of 571 patients comparing continuous vs. interrupted suture techniques. Ann Surg 197(2):238-43, 1983. e-Pub 1983. PMID: 6297417.
205. Abo T, Miller CA, Gartland GL, Balch CM. Differentiation stages of human natural killer cells in lymphoid tissues from fetal to adult life. J Exp Med 157(1):273-84, 1983. e-Pub 1983. PMID: 6848618.
206. Balch CM, Dougherty PA, Tilden AB. Excessive prostaglandin E2 production by suppressor monocytes in head and neck cancer patients. Ann Surg 196(6):645-50, 1982. e-Pub 1982. PMID: 6216863.
207. Tilden AB, Balch CM. A comparison of PGE2 effects on human suppressor cell function and on interleukin 2 function. J Immunol 129(6):2469-73, 1982. e-Pub 1982. PMID: 6216284.
208. Balch CM, Soong SJ, Milton GW, Shaw HM, McGovern VJ, Murad TM, McCarthy WH, Maddox WA. A comparison of prognostic factors and surgical results in 1,786 patients with localized (stage I) melanoma treated in Alabama, USA, and New South Wales, Australia. Ann Surg 196(6):677-84, 1982. e-Pub 1982. PMID: 7149819.
209. Abo T, Balch CM. Characterization of HNK-1+ (Leu-7) human lymphocytes. III. Interferon effects on spontaneous cytotoxicity and phenotypic expression of lymphocyte subpopulations delineated by the monoclonal HNK-1 antibody. Cell Immunol 73(2):376-84, 1982. e-Pub 1982. PMID: 7159933.
210. Abo T, Balch CM. Characterization of HNK-1+ (Leu-7) human lymphocytes. II. Distinguishing phenotypic and functional properties of natural killer cells from activated NK-like cells. J Immunol 129(4):1758-61, 1982. e-Pub 1982. PMID: 7108226.
211. Tilden AB, Balch CM. Immune modulatory effects of indomethacin in melanoma patients are not related to prostaglandin E2-mediated suppression. Surgery 92(3):528-32, 1982. e-Pub 1982. PMID: 6287658.
212. Abo T, Roder JC, Abo W, Cooper MD, Balch CM. Natural killer (HNK-1+) cells in Chediak-Higashi patients are present in normal numbers but are abnormal in function and morphology. J Clin Invest 70(1):193-7, 1982. e-Pub 1982. PMID: 7085883.
213. Balch CM, Smalley RV, Bartolucci AA, Burns D, Presant CA, Durant JR. A randomized prospective clinical trial of adjuvant C. parvum immunotherapy in 260 patients with clinically localized melanoma (Stage I): prognostic factors analysis and preliminary results of immunotherapy. Cancer 49(6):1079-84, 1982. e-Pub 1982. PMID: 7037155.
214. Budowle B, Barger BO, Balch CM, Go RC, Roseman JM, Acton RT. Associations of properdin factor B with melanoma. Cancer Genet Cytogenet 5(3):247-51, 1982. e-Pub 1982. PMID: 6917774.
215. Bonewald L, Wang AC, Terry E, Zwerner R, Balch CM, Ades EW. Molecular comparison of mouse Thy-1 and its human homologue. Mol Immunol 19(3):497-501, 1982. e-Pub 1982. PMID: 6124880.
216. Milton GW, Shaw HM, McCarthy WH, Pearson L, Balch CM, Soong SJ. Prophylactic lymph node dissection in clinical stage I cutaneous malignant melanoma: results of surgical treatment in 1319 patients. Br J Surg 69(2):108-11, 1982. e-Pub 1982. PMID: 7059764.
217. Abo T, Cooper MD, Balch CM. Postnatal expansion of the natural killer and keller cell population in humans identified by the monoclonal HNK-1 antibody. J Exp Med 155(1):321-6, 1982. e-Pub 1982. PMID: 7054358.
218. Balch CM, Loken MR, Dougherty PA, Ades EW. Expression of a 16,000 molecular weight antigen on human suppressor T lymphocytes. Cell Immunol 64(1):84-92, 1981. e-Pub 1981. PMID: 6457697.
219. Abo T, Balch CM. A differentiation antigen of human NK and K cells identified by a monoclonal antibody (HNK-1). J Immunol 127(3):1024-9, 1981. e-Pub 1981. PMID: 6790607.
220. Tilden AB, Balch CM. Indomethacin enhancement of immunocompetence in melanoma patients. Surgery 90(1):77-84, 1981. e-Pub 1981. PMID: 6972628.
221. Balch CM. Measuring melanomas--a tribute to Alexander Breslow. J Am Acad Dermatol 5(1):96-7, 1981. e-Pub 1981. PMID: 7024338.
222. Manci EA, Balch CM, Murad TM, Soong SJ. Polypoid melanoma, a virulent variant of the nodular growth pattern. Am J Clin Pathol 75(6):810-5, 1981. e-Pub 1981. PMID: 7258141.
223. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma: III. Prognostic factors in melanoma patients with lymph node metastases (stage II). Ann Surg 193(3):377-88, 1981. e-Pub 1981. PMID: 7212800.
224. Balch CM, Ades EW, Loken MR, Shore SL. Human "null" cells mediating antibody-dependent cellular cytotoxicity express T lymphocyte differentiation antigens. J Immunol 124(4):1845-51, 1980. e-Pub 1980. PMID: 6767776.
225. Ades EW, Zwerner RK, Acton RT, Balch CM. Isolation and partial characterization of the human homologue of Thy-1. J Exp Med 151(2):400-6, 1980. e-Pub 1980. PMID: 6153212.
226. Balch CM. Oral and cutaneous melanoma: clinical recognition, pathological features, and prognostic factors. Ala J Med Sci 17(1):51-5, 1980. e-Pub 1980. PMID: 7386793.
227. Ades EW, Ferrone S, Balch CM. Immunochemical characterization of a human B lymphocyte differentiation antigen (p65). Scand J Immunol 12(6):519-23, 1980. e-Pub 1980. PMID: 6972571.
228. Balch CM, Soong SJ, Murad TM, Ingalls AL, Maddox WA. A multifactorial analysis of melanoma. II. Prognostic factors in patients with stage I (localized) melanoma. Surgery 86(2):343-51, 1979. e-Pub 1979. PMID: 462379.
229. Ades EW, Dougherty P, Shore SL, Balch CM. E-rosette receptors induced by phytohemagglutinin on human K cells expressing T-cell surface antigens. Cell Immunol 44(1):179-85, 1979. e-Pub 1979. PMID: 313256.
230. Balch CM, Murad TM, Soong SJ, Ingalls AL, Richards PC, Maddox WA. Tumor thickness as a guide to surgical management of clinical stage I melanoma patients. Cancer 43(3):883-8, 1979. e-Pub 1979. PMID: 427730.
231. Diethelm AG, Chambers L, Sachs G, Balch CM, Phillips SJ, Thiry C. The preparation and immunosuppressive properties of equine antihuman thymocyte membrane immunoglobulin G. Surgery 85(2):159-65, 1979. e-Pub 1979. PMID: 105416.
232. Durkin WJ, Ghanta VK, Balch CM, Davis DW, Hiramoto RN. A methodological approach to the prediction of anticancer drug effect in humans. Cancer Res 39(2 Pt 1):402-7, 1979. e-Pub 1979. PMID: 761212.
233. Ades EW, Dougherty PA, Balch CM. Partial immunochemical characterization of human B-lymphocyte differentiation antigen (BDA-1). Adv Exp Med Biol 121B:239-46, 1979. e-Pub 1979. PMID: 121032.
234. Balch CM. Recent advances in human cellular immunobiology. Surgical Clinics of North America 59(2):235-252, 1979. e-Pub 1979.
235. Ades EW, Balch CM. A molecular approach delineating surface markers on human T-lymphocytes. Adv Exp Med Biol 114:593-8, 1979. e-Pub 1979. PMID: 111484.
236. Balch CM, Dougherty PA, Vogler LB, Ades EW, Ferrone S. A new B cell differentiation antigen (BDA) on normal and leukemic human B lymphocytes that is distinct from known DR (Ia-like) antigens. J Immunol 121(6):2322-8, 1978. e-Pub 1978. PMID: 102693.
237. Dougherty PA, Ades EW, Balch CM. Independent expression of human T cell differentiation antigens and E rosette receptor on phytohemagglutinin-stimulated T lymphocytes. Transplantation 26(6):434-7, 1978. e-Pub 1978. PMID: 310593.
238. Balch CM, Murad TM, Soong SJ, Ingalls AL, Halpern NB, Maddox WA. A multifactorial analysis of melanoma: prognostic histopathological features comparing Clark's and Breslow's staging methods. Ann Surg 188(6):732-42, 1978. e-Pub 1978. PMID: 736651.
239. Ades EW, Bukacek A, Zwerner RK, Dougherty PA, Balch CM. Expression of two differentiation antigens on normal and cultured human T cells. J Immunol 121(2):513-9, 1978. e-Pub 1978. PMID: 355545.
240. Balch CM, Dougherty PA, Dagg MK, Diethelm AG, Lawton AR. Detection of human T cells using anti-monkey thymocyte antisera. Tissue distribution and evidence for antigenic heterogeneity. Clin Immunol Immunopathol 8(3):448-60, 1977. e-Pub 1977. PMID: 71961.
241. Balch CM, Dougherty PA, Vogler LB. Cross-reacting anti-monkey lymphocyte antisera: a simplified immunofluorescence approach for detecting human T and B lymphocytes. J Surg Res 22(6):636-42, 1977. e-Pub 1977. PMID: 405531.
242. Balch CM, Marzoni FA. Skin transplantation during the pre-Reverdin era, 1804-1869. Surg Gynecol Obstet 144(5):766-73, 1977. e-Pub 1977. PMID: 322349.
243. Balch CM, Dagg MK, Cooper MD. Cross-reactive T-cell antigens among mammalian species. J Immunol 117(2):447-9, 1976. e-Pub 1976. PMID: 59778.
244. Diethelm AG, Sterling WA, Balch CM, Clark EC. Preservation of cadaver kidneys using hypothermic, hyperosmolar, intracellular washout solution. Transplantation 21(5):417-20, 1976. e-Pub 1976. PMID: 775707.
245. Diethelm AG, Chambers LM, Balch CM, Phillips SJ. Preparation and immunosuppressive potency of equine anti-human thymocyte membrane IgG. Postgrad Med J 52(5 Suppl):55-8, 1976. e-Pub 1976. PMID: 825846.
246. Dubovsky EV, Logic JR, Diethelm AG, Balch CM, Tauxe WN. Comprehensive evaluation of renal function in the transplanted kidney. J Nucl Med 16(12):1115-20, 1975. e-Pub 1975. PMID: 1104781.
247. Diethelm AG, Sterling WA, Balch CM, Clark EC. Human cadaver kidney preservation using hypothermic hyperosmolar, intracellular washout solution. Proc Clin Dial Transplant Forum 5:26-32, 1975. e-Pub 1975. PMID: 785459.
248. Insel RA, Melewicz FM, La Via MF, Balch CM. Morphology, surface markers, and in vitro responses of a human leukemic T cell. Clin Immunol Immunopathol 4(3):382-91, 1975. e-Pub 1975. PMID: 127678.
249. Balch CM, Morgan JM, Sterling WA, Bradley EL, Diethelm AG. Kidney transplantation in patients with end stage congenital renal disease. Report of eighteen cases and review of the Organ Transplant Registry. Am J Surg 130(3):303-8, 1975. e-Pub 1975. PMID: 1101718.
250. Balch CM, Karp RB. Blood group compatibility and aortic valve allotransplantation in man. J Thorac Cardiovasc Surg 70(2):256-9, 1975. e-Pub 1975. PMID: 807781.
251. Balch CM, Feldman JD. Origin and development of rat thymus-dependent (T) lymphocytes. J Immunol 112(1):87-95, 1974. e-Pub 1974. PMID: 4590830.
252. Balch CM, Feldman JD. Thymus-dependent (T) lymphocytes in the rat. J Immunol 112(1):79-86, 1974. e-Pub 1974. PMID: 4590829.
253. Balch CM, Wilson CB, Lee S, Feldman JD. Thymus-dependent lymphocytes in tissue sections of rejecting rat renal allografts. J Exp Med 138(6):1584-90, 1973. e-Pub 1973. PMID: 4586981.
254. Balch CM, Silver D. Foreign bodies in the appendix. Report of eight cases and review of the literature. Arch Surg 102(1):14-20, 1971. e-Pub 1971. PMID: 5538761.
255. Balch CM, Ikoma N. Steps to Getting Your Manuscript Published in a High Quality Medical Journal.

Invited Articles

1. Shanafelt T, Sloan J, Satele D, Balch C. Why do surgeons consider leaving practice?. J Amer Coll Surg 212:421-422, 2011. e-Pub 2011.
2. Balch CM, Shanafelt T. Combating stress and burnout in surgical practice: A review. Thorac Surg Clin 21(3):417-430, 2011. e-Pub 2011.
3. Balch CM, Gershenwald JE, Soong SJ, Thompson JF. Update on the Melanoma Staging System. The Importance of Sentinel Node and Primary Tumor Mitotic Rate. J Surg Oncol 104:379-385, 2011. e-Pub 2011.
4. Balch CM, Mihm MC, Gershenwald JE, Soong SJ. The revised melanoma staging system. The Melanoma Letter 28(3):1-6, 2010. e-Pub 2010.
5. Balch CM, Russell TR. ACS Patterns of Care Survey, Part III: Use of Surgical Instruments and Devices among Surgical Specialities. ACS Bulletin 94:24-29, 2009. e-Pub 2009.
6. Balch CM, Russell TR. ACS Patterns of Care Survey, Part II Prescribing Habits among Surgical Specialities. ACS Bulletin 93:11-15, 2008. e-Pub 2008.
7. Balch CM, Russell TR. A Patterns of Care Survey: Contemporary Surgeons Bring Technical and Cognitive Skills to Patient Care. ACS Bulletin 93:17-19, 2008. e-Pub 2008.
8. Lange JR, Balch CM. Screening for Cutaneous Melanoma. Surg Oncol Clin N Am 14:799-811, 2005. e-Pub 2005.
9. Kim CJ, Reintgen DS, Balch CM. The New Melanoma Staging System. Journal of the Moffitt Cancer Center 9:9-15, 2002. e-Pub 2002.
10. Balch CM, Cascinelli N. The New Melanoma Staging System. Tumori 87:S64-68, 2001. e-Pub 2001.
11. Balch CM, Slominski A, Wortsman J, Carlson AJ, Matsuoko LY, Mihm MC. Malignant Melanoma: An Update. Arch Pathol Lab Med:125, 2001. e-Pub 2001.
12. Miller MJ, Balch CM. "Iris" technique for immediate umbilical reconstruction. Plan & Recon Surg 92:754-756, 1993. e-Pub 1993.

Review Articles

1. Balch CM. Ernst Bertner: A Surgeon with Prescient Vision for the Largest Medical Center in the World. Ann Surg Oncol 31(5):2833-2855, 2024. e-Pub 2024. PMID: 38324237.
2. Are, C, Murthy, SS, Sullivan, R, Schissel, M, Chowdhury, S, Alatise, OI, Anaya, DA, Are, M, Balch, CM, Bartlett, DL, Brennan, MF, Cairncross, L, Clark, M, Deo, SV, Dudeja, V, D'Ugo, D, Fadhil, I, Giuliano, AE, Gopal, S, Gutnik, L, Ilbawi, AM, Jani, P, Kingham, TP, Lorenzon, L, Leiphrakpam, P, León, A, Said, HM, McMasters, KM, Meltzer, DO, Mutebi, M, Zafar, SN, Naik, V, Newman, LA, Oliveira, AF, Park, DJ, Pramesh, CS, Rao, S, Subramanyeshwar Rao, T, Bargallo-Rocha, E, Romanoff, A, Rositch, AF, Rubio, IT, Salvador de Castro Ribeiro, H, Sbaity, E, Senthil, M, Smith, L, Toi, M, Turaga, KK, Yanala, U, Yip, CH, Zaghloul, AS, Anderson, BO. Global Cancer Surgery. The lancet oncology 24(12):e472-e518, 2023. e-Pub 2023. PMID: 37924819.
3. Balch CM, Winchester DP, Copeland EM. The Pivotal Leadership of Doctors R. Lee Clark and Murray M. Copeland in Transforming the Commission on Cancer (1955-1965). Ann Surg Oncol 29(9):5401-5421, 2022. e-Pub 2022. PMID: 35661955.
4. Jones RP, Are C, Hugh TJ, Grünhagen DJ, Xu J, Balch CM, Poston GJ. Reshaping the critical role of surgeons in oncology research. Nat Rev Clin Oncol. e-Pub 2019. PMID: 30617343.
5. McIntosh K, Balch C, Tiwari AK. Tackling multidrug resistance mediated by efflux transporters in tumor-initiating cells. Expert Opin Drug Metab Toxicol 12(6):633-44, 2016. e-Pub 2016. PMID: 27116192.
6. Wong SL, Balch CM, Hurley P, Agarwala SS, Akhurst TJ, Cochran A, Cormier JN, Gorman M, Kim TY, McMasters KM, Noyes RD, Schuchter LM, Valsecchi ME, Weaver DL, Lyman GH, Clinical Oncology ASO, Surgical Oncology SO. Sentinel lymph node biopsy for melanoma: American Society of Clinical Oncology and Society of Surgical Oncology joint clinical practice guideline. J Clin Oncol 30(23):2912-8, 2012. e-Pub 2012. PMID: 22778321.
7. Balch CM, Soong SJ, Atkins MB, Buzaid AC, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. An evidence-based staging system for cutaneous melanoma. CA Cancer J Clin 54(3):131-49; quiz 182-4, 2004. e-Pub 2004. PMID: 15195788.
8. Balch CM, Sober AJ, Soong SJ, Gershenwald JE, Staging Committee AM. The new melanoma staging system. Semin Cutan Med Surg 22(1):42-54, 2003. e-Pub 2003. PMID: 12773013.
9. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. New TNM melanoma staging system: linking biology and natural history to clinical outcomes. Semin Surg Oncol 21(1):43-52, 2003. e-Pub 2003. PMID: 12923915.
10. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, McMasters KM, Mihm MF, Morton DL, Reintgen DS, Ross MI, Sober A, Thompson JA, Thompson JF. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19(16):3635-48, 2001. e-Pub 2001. PMID: 11504745.
11. McMasters KM, Reintgen DS, Ross MI, Gershenwald JE, Edwards MJ, Sober A, Fenske N, Glass F, Balch CM, Coit DG. Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J Clin Oncol 19(11):2851-5, 2001. e-Pub 2001. PMID: 11387357.
12. Reintgen D, Balch CM, Kirkwood J, Ross M. Recent advances in the care of the patient with malignant melanoma. Ann Surg 225(1):1-14, 1997. e-Pub 1997. PMID: 8998115.
13. Mansfield PF, Lee JE, Balch CM. Cutaneous melanoma: current practice and surgical controversies. Curr Probl Surg 31(4):253-374, 1994. e-Pub 1994. PMID: 8143489.
14. Cockerell CJ, Howell JB, Balch CM. Think melanoma. South Med J 86(12):1325-33, 1993. e-Pub 1993. PMID: 8272906.
15. Ross MI, Reintgen D, Balch CM. Selective lymphadenectomy: emerging role for lymphatic mapping and sentinel node biopsy in the management of early stage melanoma. Semin Surg Oncol 9(3):219-23, 1993. e-Pub 1993. PMID: 8516607.
16. Balch CM, Singletary SE, Bland KI. Clinical decision-making in early breast cancer. Ann Surg 217(3):207-25, 1993. e-Pub 1993. PMID: 8383953.
17. Ross MI, Balch CM. The current management of cutaneous melanoma. Adv Surg 24:139-200, 1991. e-Pub 1991. PMID: 1996522.
18. Parkinson DR, Talpaz M, Lee KH, Legha S, Markowitz AB, Itoh K, Balch CM, Murray JL, Zukiwski AA, Benjamin RS. Interleukin-2 alone and in combination with other cytokines in melanoma: the investigational approach at the University of Texas M.D. Anderson Cancer Center. Cancer Treat Rev 16 Suppl A:39-48, 1989. e-Pub 1989. PMID: 2670214.
19. Boddie AW, McBride CM, Balch CM. Gastric cancer. Am J Surg 157(6):595-606, 1989. e-Pub 1989. PMID: 2658642.
20. Balch CM. The role of elective lymph node dissection in melanoma: rationale, results, and controversies. J Clin Oncol 6(1):163-72, 1988. e-Pub 1988. PMID: 3275746.
21. Balch CM. Cutaneous melanoma: a review of clinical management. Tex Med 83(3):70-8, 1987. e-Pub 1987. PMID: 3554593.
22. Balch CM. [Diagnosis and prognosis of malignant melanoma]. Dtsch Med Wochenschr 110(46):1783-6, 1985. e-Pub 1985. PMID: 2414087.
23. Hersey P, Balch CM. Current status and future prospects for adjuvant therapy of melanoma. Aust N Z J Surg 54(4):303-15, 1984. e-Pub 1984. PMID: 6207805.
24. Balch CM, Ades EW. Heterogeneity of cell surface xenoantigens on human T lymphocytes. J Reticuloendothel Soc 25(6):635-51, 1979. e-Pub 1979. PMID: 385868.
25. Balch CM, Maddox WA. The logic of adjunctive therapy in surgical patients with resectable cancer. South Med J 71(8):951-5, 957, 1978. e-Pub 1978. PMID: 356271.
26. Balch CM, Diethelm AG. The pathophysiology of renal allograft rejection: a collective review. J Surg Res 12(5):350-77, 1972. e-Pub 1972. PMID: 4554836.

Other Articles

1. Sladden MJ, Balch C, Handiside T, Hollis S, Lens MB Surgical Excision Margins for Primary Cutaneous Melanoma. Cochrane Review(11), 2015.
2. Balch CM Book Report on "Surgical Mentoring: Building Tomorrow's Leaders". Annals of Surgery, 2011.

Editorials

1. Audisio RA, Balch CM. Why Can't Surgeons Treat Older Patients the Same as Younger Patients. Ann Surg Oncol 23(13):4123-4125, 2016. PMID: 27456957.
2. Balch CM, Poston GJ, Coit D, Audisio R. Training a new generation of surgeons worldwide who are also oncologists. Chin Clin Oncol 5(4):58, 2016. PMID: 27558256.
3. Balch CM, Poston GJ. Training a new generation of Surgical Oncologists worldwide. Lancet Oncol 17(6):700-701, 2016. PMID: 27299262.
4. Audisio RA, Balch CM. Why Can't Surgeons Treat Older Patients the Same as Younger Patients?. Ann Surg Oncol, 2016.
5. Balch CM, Nelson H, Niederhuber J, Klimberg S. Limitations and Barriers to the Conduct of Surgical Oncology Clinical Trials. Nature Oncology Reviews 13:6-8, 2016.
6. Liao N, Hunt KK, Balch CM. Management of invasive and non-invasive breast cancer in the United States and China. Chinese Clinical Oncology 5:30, 2016.
7. Balch CM, Hoon DS. Donald L. Morton, MD: A Legendary Surgical Oncologist and Consummate Investigator. CritRev Oncog 21:3-5, 2016.
8. Balch CM, Hoon DS. Donald L Morton, MD....A Legendary Surgical Oncologist and Consummate Investigator. Crit Rev Oncog 21(1-2):3-5, 2016. PMID: 27480997.
9. Balch CM, Roh M, Klimberg VS, Whippen D. Annals of Surgical Oncology: The First 20 Years. Ann Surg Oncol 21:3708-3712, 2014.
10. Balch CM. Foreword. Breast, Endocrine, and Surgical Oncology. Coventry BJ Ed:VII-VIII, 2014.
11. Balch CM, Gershenwald JE. Clinical value of the sentinel-node biopsy in primary cutaneous melanoma. N Engl J Med 370:663-664, 2014.
12. Balch CM, Roh M, Klimberg VS, Whippen D. Memorium: Donald L. Morton (1934-2014). An Icon in Surgical Oncology. Ann Surg Oncol 21:1413-1416, 2014.
13. Balch CM. Balancing benefits and risks of melanoma treatment: What do we tell our patients?. Oncology 27:1026-1027, 2013.
14. Balch CM. Seng-jaw Soong (1943-2012) In memoriam. Statistician and Statistician Extraordinaire. Annals of Surgical Oncology 20:2453-2456, 2013.
15. Balch CM, Balch GC, Sharma RR. Identifying early melanomas at higher risk for metastases. J Clin Oncol 30:1406-1407, 2012.
16. Balch CM. Donald L. Morton: A living legend in surgical oncology. J Surg Oncol 104(4):338-340, 2011.
17. Balch CM. Co-Managing an organ transplant and melanoma. Arch Surg 146:1347-1348, 2011.
18. Balch CM, Bechamps G. Substance abuse among surgeons: The perils of losing your credentials. Arch Surg 146:1291-1292, 2011.
19. Lange JR, Kang S, Balch CM. Melanoma in the older patient: Measuring frailty as an index of survival. Ann Surg Oncol 18:3531-3532, 2011.
20. Balch CM, Shanafelt TS. The dynamic tension between success in a surgical career and personal wellness: How can we succeed in a stressful environment and a "culture of bravado". Ann Surg Oncol 18(5):1213-1216, 2011.
21. Balch CM, Shanafelt TD. Burnout among surgeons: does specialty make a difference?. ArchSurg 146:385-386, 2011.
22. Shanafelt T, Sloan J, Balch CM. Why do surgeons consider leaving practice?. JACS 212:421-422, 2011.
23. Balch CM. Burnout: What community cancer centers need to know. Oncology Issues, 2010.
24. Balch CM, Whippen D, Klimburg VS, Roh M. The global journal for surgeons treating cancer. Ann Surg Oncol 17:2255-2259, 2010.
25. Jacobs LK, Balch CM, Soong SJ. Predicting the risk of axillary nodal metastases, and their use in selecting breast surgery options. J Clin Oncol 27:5673-5375, 2009.
26. Balch CM, Jacobs L. Mastectomies on the rise for breast cancer: the tide is changing. Annals of Surgical Oncology 16:2669-2672, 2009.
27. Balch CM. Microscopic satellites around a primary melanoma: another piece of the puzzle in melanoma staging. Ann Surg Oncol 15(5):1092-1094, 2009.
28. Jacobs LK, Lange JR, Balch CM. Sorting through the heterogeneity of recurrent melanoma. Annals of Surgical Oncology 15:1280-1281, 2008.
29. Balch CM, S-J S. Predicting outcomes in metastatic melanoma. Journal of Clinical Oncology 26:168-169, 2008.
30. Sober AJ, Balch CM. Method of biopsy and incidence of positive margins in primary melanoma. Ann Surg Oncol 14:274-275, 2007.
31. Jacobs LK, Balch C. Can a small nodal metastasis reliably alter intraoperative risk/benefit decision making in breast cancer surgery?. Ann Surg Oncol 14:3040-3042, 2007.
32. Morton DL, Scheri RP, Balch CM. Can completion lymh node dissection be avoided for a positive sentinel node in melanoma?. Ann Surg Oncol 14:2437-2439, 2007.
33. Bland KI, Rikkers LF, Lillemoe KD. Mandatory registration of clinical trials. J Am Coll Surg 204(4):654-655, 2007.
34. Balch CM. Prescribing patterns of surgical oncologists: are we surgeons, oncologists or both?. Ann Surg Oncol 14:2685-2686, 2007.
35. Balch CM, Copeland E. Stress and burnout among surgical oncologists: a call for personal wellness and a supportive workplace environment. Ann Surg Oncol 14:3029-3032, 2007.
36. Balch CM, Ross MI, Cascinelli N, S-J S. Empirically-based surgery versus evidence-based surgery: excision margins for melanoma as a prototype for establishing standards of care through clinical trials. Arch Surg 142:891-893, 2007.
37. Bland KI, Bowden TA, Rikkers LF, Balch CM. Consensus statement on surgery journal authorship. Journal of Thoracic and Cardiovascular Surgery 131(6):1221-1222, 2007.
38. Balch CM, Cascinelli N. Sentinel-node biopsy in melanoma. The New England Journal of Medicine 355:1370-1371, 2006.
39. Balch CM. Randomized clinical trials in surgery: Why do we need them?. The Journal of Thoracic and Cardiovascular Surgery 132:241-242, 2006.
40. Sharfman W, Lange J, Balch CM. Pediatric melanoma. Pediatric Blood Cancer 44:431-432, 2005.
41. Tyler DS, Balch CM. Nomograms and staging in melanoma: new tools for better predicting outcomes. Ann Surg Oncol 12:267-269, 2005.
42. Balch CM. Foreword for Romanian Melanoma Book. Melanomul Malign:vii-viii, 2003.
43. Balch CM, Lange J, Sharfman W, Sauder D. Malignant melanoma in children: should we treat them as adults?. Oncology 17:1008, 2003.
44. Balch CM, Roh MS, Bland KI, Brennan MF, EMrd C, Morton DL, Niederhuber JE, Pollock RE. Annals of Surgical Oncology impact factor/rating has dramatically increased. Ann Surg Oncol 10:1-, 2003.
45. TA Jr PHJB, Rikkers LF, Balch CM, Oran CH, Murie JA, Pories WJ, Buechler MW, Neoptolemos JP, Fazio VW, Schwartz SI, Cameron JL, Kelly KA, Grosfeld JL, McFadden DW, Souba WW, Jr PB, Johnson KW, Rutherford RB, Arregui ME, Scott-Conner CE, Warshaw AL, Sarr MG, Cushieri A, MacFadyen BV, Rk T. Consensus statement on scientific data from clinical trials and investigators' responsibilities and rights. Br J Surg 89:678-679, 2002.
46. Balch CM. Surgical Margins for Melanoma: is 2 cm too much?. ANZ Journal of Surgery 72:251-252, 2002.
47. TA Jr PHJB, Rikkers LF, Balch CM, Oran CH, Murie JA, Pories WJ, Buechler MW, Neoptolemos JP, Fazio VW, Schwartz SI, Cameron JL, Kelly KA, Grosfeld JL, McFadden DW, Souba WW, Jr PB, Johnson KW, Rutherford RB, Arregui ME, Scott-Conner CE, Warshaw AL, Sarr MG, Cushieri A, MacFadyen BV, Rk T. Consensus statement on scientific data from clinical trials and investigators' responsibilities and rights. Ann Surg Oncol 9:421-422, 2002.
48. TA Jr PHJB, Rikkers LF, Balch CM, Oran CH, Murie JA, Pories WJ, Buechler MW, Neoptolemos JP, Fazio VW, Schwartz SI, Cameron JL, Kelly KA, Grosfeld JL, McFadden DW, Souba WW, Jr PB, Johnson KW, Rutherford RB, Arregui ME, Scott-Conner CE, Warshaw AL, Sarr MG, Cushieri A, MacFadyen BV, Rk T. Consensus statement on scientific data from clinical trials and investigators' responsibilities and rights. J Am Coll Surg 194:851-852, 2002.
49. TA Jr PHJB, Rikkers LF, Balch CM, Oran CH, Murie JA, Pories WJ, Buechler MW, Neoptolemos JP, Fazio VW, Schwartz SI, Cameron JL, Kelly KA, Grosfeld JL, McFadden DW, Souba WW, Jr PB, Johnson KW, Rutherford RB, Arregui ME, Scott-Conner CE, Warshaw AL, Sarr MG, Cushieri A, MacFadyen BV, Rk T. Consensus statement on scientific data from clinical trials and investigators' responsibilities and rights. Arch Surg 137:639-640, 2002.
50. TA Jr PHJB, Rikkers LF, Balch CM, Oran CH, Murie JA, Pories WJ, Buechler MW, Neoptolemos JP, Fazio VW, Schwartz SI, Cameron JL, Kelly KA, Grosfeld JL, McFadden DW, Souba WW, Jr PB, Johnson KW, Rutherford RB, Arregui ME, Scott-Conner CE, Warshaw AL, Sarr MG, Cushieri A, MacFadyen BV, Rk T. Consensus statement on scientific data from clinical trials and investigators' responsibilities and rights. World J Surg 26:637-638, 2002.
51. Balch CM, Mihm M. Editorial Commentary by the EORTC Melanoma Group on the AJCC Melanoma Staging System. Annals of Oncology 12:9-11, 2001.
52. Balch CM. Duplicate Submission and Scientific Fraud. Annals of Surgical Oncology 8:381, 2001.
53. Balch CM, Morton DL. Second-Time Surgery for Stage IV Sarcoma. Journal of American College of Surgeons 191:193-195, 2000.
54. Balch CM, Ross MI. Sentinel lymphadenectomy for melanoma - Is it a substitute for elective lymphadenectomy?. Annals of Surgical Oncology 6:416-417, 1999.
55. Balch CM, Ross MI. Melanoma patients with iliac nodal metastases can be cured. Annals of Surgical Oncology 6:230-231, 1999.
56. Balch CM, Roh M, Fried K. New and Improved Annals of Surgical Oncology. Annals of Surgical Oncology 6:1, 1999.
57. Balch CM. Palliative surgery for stage IV melanoma: Is it a primary treatment?. Journal of American College of Surgeons 6:623-624, 1999.
58. Balch CM, Ross MI. The importance of lymphatic anatomy in melanoma - a recurrence of clinical area sentinel lymph node technology. Journal of American College of Surgeons 189:204-206, 1999.
59. Balch CM. Foreword. A Woman's Decision. Breast Care, Treatment, and Reconstruction, 1998.
60. Buzaid AC, Balch CM. Polymerase chain reaction for detection of melanoma in peripheral blood: too early to assess clinical value. J Nation Ca Inst 88:569-570, 1996.
61. Balch CM, Buzaid AC. Finally, a successful therapy for high-risk melanoma. JCO 14:1-3, 1996.
62. Balch CM. The breast implant story: mendacity and avarice have prevailed. Breast Diseases: A Year Book Quarterly 5:15, 1995.
63. Balch CM. The needle biopsy should replace open excisional biopsy, but will the surgeon's role in coordinating breast cancer treatment be diminished?. Ann Surg Oncol 2:191-192, 1995.
64. Balch CM. How patient referral bias can confuse interpretation of clinical results: elective lymph node dissections at the Sydney Melanoma Unit. J Am Col Surg 180:490-492, 1995.
65. Balch CM. Foreward. Pathology of melanocytic nevi and malignant melanoma. RL Barnhill,, 1995.
66. Balch CM, Bland KI, Brennan MF, Cameron JL, Chabner BA, Copeland III EM, Hoskins WJ, Karakousis CP, Niederhuber JE, Pollock RE, Richie JP, Roth JA, Shah JP, Shuck JM, Winchester DP. What is a surgical oncologist?. Ann Surg Oncol 1:2-4, 1994.
67. Balch CM, Roh MS, Hubona CM. The Annals of Surgical Oncology: An oncology journal for surgeons. Ann Surg Oncol 1:1, 1994.
68. Balch CM, Roh MS. Approaches to the opposite breast after mastectomy. Ann Surg Oncol 1(6):453, 1994.
69. Balch CM, Spear S. The controversy about silicone gel-filled prosthesis: What do we tell our patients?. Breast Diseases: A Year Book Quarterly 3:14-15, 1992.
70. Balch CM, Perez CA. Management of breast cancer recurrences after breast conservation. Breast Diseases: A Year Book Quarterly 2:14-15, 1990.
71. Balch CM. Screening for asymptomatic metastatic breast cancer: Are we ordering too many tests?. Breast Diseases: A Year Book Quarterly 1:12-14, 1990.
72. Balch CM. Axillary lymph node dissection: differences in goals and techniques when treating melanoma and breast cancer. Surgery 108:118-119, 1990.
73. Balch CM. Biology of metastasis - introduction. Cancer and Metastasis Reviews 8(2):123, 1989.
74. Balch CM, Singletary SE. Adjuvant therapy for node-negative breast cancer patients: Who benefits?. Arch Surg 123:1189-1190, 1988.
75. Balch CM. A Worldwide Comparison of Prognostic Factors in Melanoma. J of Dermatologic Surgery and Oncol 11(8):773-774, 1985.
76. Balch CM. Medial information-service via telephone. Alabama Journal of Medical Sciences 22(1):106-107, 1985.

Abstracts

1. Balch CM, Poston GJ. Training a new generation of Surgical Oncologists worldwide. Lancet Oncology 17(6):700-701, 2016. e-Pub 2016. PMID: 27299262.
2. Mokdad A, Balch GC, Hirsch H, Choti MA, Balch CM. Infectious complications following colorectal cancer surgery are associated with worse long-term survival. Ann Surg Oncol 23, 2016. e-Pub 2016.
3. Borja NA, El Mokdad A, Nassour I, Balch CM. Pelvic exenteration can be performed safely: A morbidity and mortality analysis of the first 90 days after surgery. Ann Surg Oncol 23, 2016. e-Pub 2016.
4. Zoras O, Lasithiotakis K, Balch CM. Uncertainties in the management of melanoma nodal metastases. Eur J Surg Oncol 41(7):811-813, 2015. e-Pub 2015. PMID: 25980747.
5. Ross MI, Balch CM. Excision Margins of Melanoma Make a Difference: New Data Supports an Old Paradigm. Ann Surg Oncol, 2015. e-Pub 2015.
6. Martinez Said H, Cuellar-Hubbe M, Villavicencio-Valencia V, Balch CM. Prognosis of Acral Lentiginous Melanoma Compared to Sun-Induced Melanoma. Ann Surg Oncol 21, 2014. e-Pub 2014.
7. Cavanaugh-Hussey MW, Mu EW, Wang T, Balch CM. Inverse relationship between melanoma deaths and sentinel node metastases by age. J Invest Derm 133, 2013. e-Pub 2013.
8. Balch CM, Gershenwald JE, Soong SJ. Update on the melanoma staging system: the importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol, 2011. e-Pub 2011.
9. Gershenwald JE, Soong SJ, Balch CM. 2010 TNM Staging System for Cutaneous Melanoma and Beyond. Ann Surg Oncol 17(6):1475-1477, 2010. e-Pub 2010.
10. Balch CM, Shanafelt TD, Sloan J. Comparisons of demographics, burnout, and career satisfaction of 407 surgical oncologists with 7475 surgeons from other specialties; an American College of Surgeons Survey. Ann Surg Oncol 17, 2010. e-Pub 2010.
11. Roh M, Whippen D, Balch CM. State of the journal 2010: Managing growth, extending our reach - now the official journal for the Society of Surgical Oncology and the American Society of Breast Surgeons. Ann Surg Oncol 17(1):1-3, 2010. e-Pub 2010. PMID: 20013314.
12. Voltura AM, Jacobs L, Balch C. Nipple-sparing mastectomy. Annals of Surgical Oncology 15, 2008. e-Pub 2008.
13. Balch CM, Soong SJ, Thompson J, Gershenwald J. Prognosis and survival of 2031 melanoma patients with nodal micrometastases. Annals of Surgical Oncology 15, 2008. e-Pub 2008.
14. Bilimoria KY, Bentrem DJ, Balch CM. Complete lymph node dissection for melanoma in the United States: widely recommended, variably utilized. Annals of Surgical Oncology 15(S2), 2008. e-Pub 2008.
15. Lange JR, Chang D, Palis B, Dy S, Balch C. Socioeconomic and demographic factors associated with the use of sentinel node biopsy and adjuvant biologic response modifiers in melanoma. J Clin Oncol 24(18S), 2006. e-Pub 2006.
16. Esche C, Pfohler C, Benoit N, Balch C. First study of BRAF mutation in the serum of melanoma patients. J Invest Derm 122, 2004. e-Pub 2004.
17. Dessureault S, Soong SJ, Ross MI, Balch CM. Improved staging of node-negative patients with intermediate to thick melanomas with the use of lymphatic mapping and sentinel lymph node biopsy. Ann Surg Oncol 9, 2002. e-Pub 2002.
18. Balch CM, Soong SJ. Melanoma in the elderly: older age as an independent prognostic factor. ASCO Proceedings 21, 2002. e-Pub 2002.
19. Balch CM, Lange JR. The revised melanoma staging system. ASCO Educational Book, 2001. e-Pub 2001.
20. Balch CM, Lange JR. Lymphatic Mapping and Sentinel Node Lymphadenectomy for Cancer - An Overview. Annals of Surgical Oncology 8(9):1S-4S, 2001. e-Pub 2001.
21. Balch CM. The New Melanoma Staging System. European Journal of Cancer 37(6), 2001. e-Pub 2001.
22. Mann GN, Chu DZJ, ChenY, Lai L, Odon-Maryon T, Balch CM. Site-specific outcome in cutaneous recurrent melanoma. Proc Ann Meet ASCO 18, 1999. e-Pub 1999.
23. Thompson W, Gershenwald J, Lee J, Mansfield P, Balch C, Ross M. Sentinel lymph node identification in melanoma patients using two techniques: dye vs dye + radiolabeled colloird. Forty-Ninth Annual Cancer Symposium, SSO, 1996. e-Pub 1996.
24. Eton O, Kharkevitch D, Gianan M, Ross M, Mansfield P, Lee J, Plager C, Papadopoulos N, Bediakan A, Buzaid A, Legha S, Benjamin RS, Balch CM. Active immunotherapy with ultraviolet-B irradiated (UVR) autologous whole melanoma cells plus DETOX in patients (pts) with metastatic melanoma. Proc Ann Meet ASCO 15, 1996. e-Pub 1996.
25. Ross MI, Buzaid A, Balch CM, S-J S, Lee J, Tinoco L, Mansfield P, Bedikian A, Eton O, Plager C, Papadopoulos N, Legha A, Benjamin R. Proposal for a new staging system for cutaneous melanoma. Proc Ann Meet ASCO 15, 1996. e-Pub 1996.
26. Kharkevitch DD, Eton O, Ross MI, Guinee VF, Balch CM. Systemic immunity in melanoma patients treated with autologous ultraviolet-B irradiated whole tumor cell vaccine with DETOX. Proc Annual Meeting AACR 36, 1995. e-Pub 1995.
27. Gutman HB, Hess KR, Kokotasakis HA, Ross MA, Guinee VF, Balch CM. Surgery for abdominal metastases of cutaneous melanoma. 1st World Congress on Advances in Oncology, Int J of Oncol 7 (Suppl), 1995. e-Pub 1995.
28. Smith TJ, BalchC, Bartolucci A, Karakousis C, Ross M, Urist M. Morbidity of primary surgery for malignant melanoma. Forty-eighth Annual Cancer Symposium P58, 1995. e-Pub 1995.
29. Smith TJ, Balch C, Bartolucci A, Karakousis C, Ross M, Urist M. Risks and complications of elective inguinal node dissection. Forty-eighth Annual Cancer Symposium 91, 1995. e-Pub 1995.
30. Karakousis CP, Balch CM, Urist MM, Ross MM, Smith TJ, Bartolucci AA. Local recurrence in malignant melanoma: long-term results of the surgical trial. Forty-eighth Annual Cancer Symposium 11, 1995. e-Pub 1995.
31. Wallack MK, Sivanandham M, Balch C, Urist M, Murray D, Rosen L, Bartolucci AA. Favorable clinical responses in subsets of patients from a randomized multi-institutional melanoma vaccine trial. Forty-eighth Annual Cancer Symposium 88, 1995. e-Pub 1995.
32. Wallack M, Sivanandham M, Balch C, Urist M, Murray D, Bartolucci A, Rosen L. A phase III randomized multi-institutional double-blind adjuvant study of vaccinia melanoma oncolysate (VMO) vs, vaccinia (V) alone in stage III melanoma. ASCO 13, 1994. e-Pub 1994.
33. Kharkevitch DD, Eton O, Itoh K, Gianan MA, Ross MI, lager C, Mansfield PF, Legha SS, Benjamin RS, Kripke ML, BalchCM. Cytotoxicity of peripheral blood lymphocytes in patients receiving autologous ultraviolet-B irradiated tumor whole cell vaccine. Proc Annual Meeting AACR 35, 1994. e-Pub 1994.
34. Vaglini M, Balch C. Isolated perfusion of the limbs for the treatment of stage IIIA-IIIB melanoma - state-of-the-art and future perspectives - presentations made at the Perfusions Meeting. Melanoma Research 4(1):3-4, 1994. e-Pub 1994.
35. Risin D, Wang TI, Kleinerman ES, Pizzini RP, Balch CM, Pellis NR. Effect of systemic immunotherapy wiht liposome-encapsulated muramyl tripeptide. Proc Annual Meeting AACR 35, 1994. e-Pub 1994.
36. Eton O, Kharkevitch DD, Korostelev A, Legha SS, Benjamin RS, Balch CM, Itoh K. Autologous ultraviolot-B irradiated (UVR) whole tumor cell vaccine plus DETOX-TM for patients with metastatic melanoma. SSO, 1994. e-Pub 1994.
37. Fujimaki W, Balch CM, Ross MI, Augustus LB, Itoh K, Filder IJ, Griffin JR, Kleinerman ES. Pilot study of liposomal muramyl tripeptide in melanoma patients: Cytokine production and activation of monocytes and lymphocytes. AACR 33, 1993. e-Pub 1993.
38. Kharkevitch DD, Itoh K, Pellis NR, Balch CM, Merritt J, Murray JL. Induction in vitro of melanoma-specific HLA-class I-restricted cytotoxicity in human peripheral blood mononuclear cells (PBMC) by anti-idiotypic antibody (Ab2). Annual Meeting AACR 34, 1993. e-Pub 1993.
39. Balch CM. Management of melanoma. Melanoma Research 3, 1993. e-Pub 1993.
40. Ross MI, Kahky MP, Mansfield PF, Balch CM Reintgen DS. Expanding the role of intraoperative lymphatic mapping and sentinel node biopsy in the management of primary melanoma. SSO, 46th Annual Cancer Symposium:52, 1993. e-Pub 1993.
41. Legha S, Ring S, Ross M, Plager C, Papadopoulos N, Eton O, Balch CM. Preoperative chemotherapy using cisplatin, vinblastine, and DTIC (CVD) for local-regional (Stage III) melanoma. AACR, 1993. e-Pub 1993.
42. Kharkevitch DD, Seito D, Balch GC, Balch CM, Itoh K. Characterization of autologous melanoma-specific T-helper 2 cells. AACR 34, 1993. e-Pub 1993.
43. Heaton KM, Rippon MB, Tucker SL, El-Naggar A, Ross MI, Balch CM. A prognostic model for stage III cutaneous melanoma utilizing DNA flow cytometry. Southwest Surgical Meeting, 1993. e-Pub 1993.
44. Risen D, Umezu Y, Pizzini R, Itoh K, Balch CM, Pellis NR. Impairment of lymphocyte motility by tumor microenvionment. Proc Annual Meeting AACR 34, 1993. e-Pub 1993.
45. Fujimaki W, Balch CM, Ross MI, Augustus LB, Itoh K, Filder IJ, Griffin JR, Kleinerman ES. Pilot study of liposomal muramyl tripeptide in melanoma patients: Cytokine production and activation of monocytes and lymphocytes. AACR 33, 1992. e-Pub 1992.
46. Legha S, Ring S, Ross M, Plager C, Papadopoulos N, Eton O, Balch CM. Preoperative chemotherapy using cisplatin, vinblastine, and DTIC (CVD) for local-regional (Stage III) melanoma. AACR 33, 1992. e-Pub 1992.
47. Kharkevitch DD, Balch GC, Seito D, Balch CM, Itoh K. Tumor-specific IL-4 and IL-6 production by CD4+ T cell line and clones from human melanoma tumor-infiltrating lymphocytes. AACR 33, 1992. e-Pub 1992.
48. Beitsch P, Balch CM. Operative morbidity and risk factor assessment in inguinal lymph node dissection for melanoma patients. Forty-fourth Annual Meeting of the Southwestern Surgical Congress, 1992. e-Pub 1992.
49. Urist MM, Balch CM, Shaw M, Maddox WA, McCarthy WH, Milton GW. Changing trends in melanoma. 35th Annual Clinical Conference, 1991. e-Pub 1991.
50. Balch CM. The role of elective lymph node dissection in melanoma: Rationale, results and controversies. 35th Annual Clinical Conference:20-1, 1991. e-Pub 1991.
51. Itoh K, Markowitz AB, Hayakawa K, Salmeron MA von Eschenbach AC, Balch CM, Parkinson DR, Legha S, Ross MI, Morita, Augustus LB. Study of adaptive therapy with tumor-infiltrating lymphocytes (TILs). AACR 32, 1991. e-Pub 1991.
52. Markowitz A, Lee KH, Doig R, Yeomans A, Parkinson D, Itoh K, von Eschenbach A, Balch CM, Gutterman J, Talpaz. Recombinant interleukin-2 (IL-2) plus recombinant interferon-alpha (IFN) in solid tumors: the MD Anderson Experience. Forty-ninth Congress of the Nordic Society of Medical Radiology, 1991. e-Pub 1991.
53. Morita T, Salmeron SA, von Eschenbach AC, Ross MI, Balch CM, Mansfield PF, Itoh K. Oligoclonal expansion of human tumor-infiltrating lymphocytes (TILs). AACR 32, 1991. e-Pub 1991.
54. Roth J, Balch CM. Thoracic surgery training: it is time for a change. Ann Thorac Surg 51, 1991. e-Pub 1991.
55. Balch CM. Selecting surgical options in melanoma patients. 35th Annual Clinical Conference:6-7, 1991. e-Pub 1991.
56. Itoh K, Parkinson DR, Hayakawa K, Salmeron MA< Augustus LB von Eschenbach A, Balch CM. Immunological study of interleukin-2-activated tumor-infiltrating lymphocytes for adoptive therapy of renal cell carcinoma. J Urol 45, 1990. e-Pub 1990.
57. Hortobagyi G, Holmes F, Frye D, Ames F, Tashima C, Buzdar A, McNeese N, Balch C. Comparison of two adjuvant chemotherapy (ACT) programs for locally advanced breast cancer (LABC): A prospective randomized trial. Proc Ann Meet Am Soc Clin Oncol 9, 1990. e-Pub 1990.
58. Legha SS, Ring S, Balch C, Plager C, Papadopoulous N, Ross M, Benjamin RS. Induction chemotherapy using cisplantin, vinblastine, and DTIC (CFD) for stage II melanoma. Sixth International Conference on Adjuvant Therapy of Cancer:40, 1990. e-Pub 1990.
59. Whitworth PW, Nii A, Itoh K, Balch CM, Fidler IJ. Cytocidal spectrum of lymphocytes infiltrating melanoma metastasis contrasts with in situ specific immunity. AACR 31, 1990. e-Pub 1990.
60. Applegate KG, BAlch CM, Itoh K, Pellis NR. Tumor-induced suppression of in vitro lymphocyte migration through collagen. AACR 31, 1990. e-Pub 1990.
61. Lamki LM, Haynie TP, Balch CM, Bhadkamka, Podoloff DA, Kim EE. Lymphoscintigraphy in the surgical management of patients with truncal melanoma: Comparison of Tc sulfur colloid with Tc human serum albumin. 36th Annual Meeting of the Society of Nuclear Medicine 249, 1989. e-Pub 1989.
62. Broadwater R, Henderson M, Bell J, Edwards N, Smith J, Swanson R, McCready D, Hardy M, Shenk R, Lawson M, Ota D, Balch C. Outpatient percutaneous central venous access in the cancer patient: A safe alternative to tunneled catheters. Southwestern Surgical Congress, 1989. e-Pub 1989.
63. Broadwater JR, Edwards MN, Kuglen CC, Hortobagyi GA, Ames FC, Balch CM. Mastectomy following preoperative chemotherapy: Strict operative criteria controls surgical morbidity. Southeastern Surgical Congress, 1989. e-Pub 1989.
64. Broadwater E, Edwards MJ, Hohn DC, Balch CM. A formal curriculum for clinical research. FOCUS on Surgical Education 6, 1989. e-Pub 1989.
65. McCready D, Broadwater R, Ross M, Pollock R, Ota D, Balch CM. Totally implanted versus percutaneous central venous access system in cancer patients: A case-control analysis of durability and cost. Clinical and Investigative Medicine 12, 1989. e-Pub 1989.
66. Itoh K, Bae, YL, Riley LB, Balch CM. Diversity of human tumor-infiltrating lymphocytes. Smith-Kline International Symposium: Critical Determinations in Cancer Progression and Metastasis, 1989. e-Pub 1989.
67. BalchCM, Bae YL, Riley LB, Itoh K. Patterns of tumor-infiltratinglymphocytes in 107 human cancers. SSO 70, 1989. e-Pub 1989.
68. Riley LB, Pellis NR< Itoh K, Schantz SP, Freedman RS, Parkinson DR, Balch CM. Cancer patients have two distinct inhibitors of LAK induction. AACR 30, 1989. e-Pub 1989.
69. Balch CM, Yoon JB, Lee BR, Itoh K. Patterns of tumor-inviltrating lymphocytes in 107 human cancers. Second International Conference on Melanoma, 1989. e-Pub 1989.
70. Legha S, Ring S, Balch C, McBride C, Plager C, Boddie A, Singletary E, Benjamin R. Induction chemotherapy using cisplatin, vinblastine and DTIC (CVD) for local or regional recurrence of melanoma: A pilot study. Second International Conference on Melanoma, 1989. e-Pub 1989.
71. T-Y K, Filaccio ML, von Eschenbach AC, Kripke ML, Balch CM, Itoh K. Clonal analysis of T lymphocytes from tumor, peripheral blood and normal kidney in renal cell carcinoma. AACR 30, 1989. e-Pub 1989.
72. Itoh K, von Eschenbach AC, T-Y K, Platsoucas CD, Balch CM. Interleukin-2-induced activation and clonal analysis of tumor-infiltrating lymphocytes of renal carcinoma. J Urol 141, 1989. e-Pub 1989.
73. Broadwater R, Henderson M, Bell J, Edwards M, Smith J, Swanson R, McCready D, Hardy M, Shenk M, Lawson M, Ota D, Balch C. Outpatient percutaneous central venous access: A safe alternative to tunneled catheters. ASCO 7, 1988. e-Pub 1988.
74. McCready DR, Hortobagyi GN, Buzdar AU, Balch CM. The prognostic significance of lymph node metastases after preoperative chemotherapy. SSO 34, 1988. e-Pub 1988.
75. McCready DR, Murray JL, Balch CM, Unger MW, Fidler IJ. Co-administration of unlabeled monoclonal antibody (MAb) enhances tumor uptake and decreased non-tumor uptake of 111-IN-labeled 96.5 in nude mice. AACR 29, 1988. e-Pub 1988.
76. Itoh K, Platsoucas CD, Balch CM. Interleukin-2 induced propagation of human tumor-infiltrating lymphocytes with cytotoxic activity restricted to fresh autologous tumor cells. AACR 129, 1988. e-Pub 1988.
77. Nanno M, Seki H, Cheng PF, Ioannides C, Balch CM, Itoh K, Platsoucas CD. Tumor infiltrating lymphocytes expressing T cell antigen receptor (TCR). Sixth Annual Texas Immunology Conference, 1988. e-Pub 1988.
78. Itoh K, Balch CM. Cell-mediated cytotoxicity against human solid tumor cells: Regulation by soluble mediators. The World Congress III on Cancers of the Skin, 1988. e-Pub 1988.
79. Itoh K, Balch CM Platsoucas CD. Spontaneous lysis of murine hybriomas expressing the OKT3 monoclonal antibody by T3+T8+Leu+T4+Leu11-peripheral blood lymphocytes. Fed Proc 46, 1987. e-Pub 1987.
80. Itoh K, Ioannides CG, Suzuki R, Platsoucas CD, Balch CM. A novel antigen expressed on murine thymocytes and cloned NK cells. J Cell Biochem Supplement 11D, 1987. e-Pub 1987.
81. Lipton A, Harvey HA, Balch CM, Antle CE, Heckard AA, Bartolucci AA, White-Hershey D. Corynebacterium parvum versus BCG adjuvant immunotherapy of stage II melanoma. Fourth European Conference on Clinical Oncology and Cancer Nursing, 1987. e-Pub 1987.
82. McCready DR, Murray JL, Balch CM. Monoclonal anitbody uptake by human melnoma: An in-vivo model. Clin Invest Med(10), 1987. e-Pub 1987.
83. McCready DR, Murray JL, Balch CM, Fidler IJ. In vitro binding does not accurately predict monoclonal antibody uptake by human melanoma xenografts in nude mice. Proc Assoc Acad Surg 21, 1987. e-Pub 1987.
84. Itoh K, Balch CM Platsoucas CD. Monocyte-independent activation and proliferation of human T cells in response to murine hybridomas expressing the OKT3 monoclonal antibody: I-2 is not required for T cell activation. Texas Immunology Conference, 1987. e-Pub 1987.
85. Balch CM. Tumor progression and metastasis - clinical implications. Journal of Cellular Biochemistry Supp 11D, 1987. e-Pub 1987.
86. Balch CM. Tumor progression and metastases. J Cell Biochem 11D, 1987. e-Pub 1987.
87. Platsoucas CD, Itoh K, Balch CM. Lysis of human solid tumor cells by monocytes and natural killer cells. Sixth International Congress of Immunology 567, 1986. e-Pub 1986.
88. Itoh K, Tilden AB, Balch CM. Cytotoxicity of human solid tumor cells by unstimulated and lymphokine-activated natural killer cells. Cell Growth Regul 4, 1985. e-Pub 1985.
89. Kheir SM, Marshall RH, Balch CM. Malignant melanoma of the hands and feet - A clinicopathologic study of 37 patients. Laboratory Investigation 52(1), 1985. e-Pub 1985.
90. Balch CM. When to consider elective lymphadenectomy in melanoma patients. J Derm Surg Oncol 11, 1985. e-Pub 1985.
91. Tilden AB, Cloud GA, Itoh K, Dougherty PA, Balch CM. Age and gender associations of granular lymphocyte (GL) subpopulations and NK activity. Fed Proc 44, 1985. e-Pub 1985.
92. Itoh K, Tilden AB, Balch CM. Collaboration of interleukin 2 (IL2) and interferon 1/2 (IFN 1/2) in the induction of human activated killer (AK) cells. Fed Proc 44, 1985. e-Pub 1985.
93. McMillan EM, Stoneking L, Abo T, Balch CM. HNK-1 positive cells in cutaneous lymphoid populations. Lab Invest 50, 1984. e-Pub 1984.
94. Urist MM, Balch CM. Intra-arterial chemotherapy for hepatoma using Adriamycin administered via an implantable constant infusion pump. ASCO 3, 1984. e-Pub 1984.
95. Kugagawa H, Ago T, Balch CM, Cooper MD. Biochemical analysis of antigenic determinants recognized on human natural killer cells by HNK-1 (Leu-7) antibody. Fed Proc 42, 1983. e-Pub 1983.
96. Acton RT, Barger BO, Go RCP, Balch CM. Phenotypes predicts onset of melanoma in a subethnic group of caucasians. Proc AACR 24, 1983. e-Pub 1983.
97. Mendelsohn SL, Abo T, Balch CM, Egan ML. Longitudinal studies suggest that natural killer (HNK-1+) cells in systemic lupus erythematosus are abnormal in number and are functionally immature. Clinical Research 31, 1983. e-Pub 1983.
98. Abo T, Miller CA, Cooper MD, Balch CM. Interleukin-2 receptor expression by activated HNK-1+ lymphocytes. Fed Proc 42, 1983. e-Pub 1983.
99. James SP, Neckers LM, Graeff AS, Cossman J, BalchCM, Strober W. Suppression of immunoglobulin synthesis by lymphocytes reactive with Leu-2a and HNK-1 in patients with Crohn's disease. Fed Proc 42, 1983. e-Pub 1983.
100. Bonewald L, Wang AC, Wang IY, Balch CM, Ades EW. Antigenic determinant shared by the human thy-1 antigen and human IgG. Fed Proc 42, 1983. e-Pub 1983.
101. Acton RT, Barger BO, Go RCP, Balch CM. HLA-DR Phenotypes predicts onset of melanoma in a subethnic group of caucasians. Proceedings of the Am Assoc for Ca Research, 1983. e-Pub 1983.
102. Balch CM, Tilden AB, Dougherty PA. Depressed levels of granular lymphocytes with natural-killer (NK) cell-function in 247 cancer-patients. Proceedings of the Am Assoc for Ca Research 24, 1983. e-Pub 1983.
103. Tilden AB, Balch CM. Studies on the mechanism of prostaglandin E2 (PGE2) mediated suppression of human lymphocyte proliferation. Fed Proc 41, 1982. e-Pub 1982.
104. Bonewald L, Wang AC, Terry E, Zwerner R, Balch CM, Ades EW. Molecular comparison of mouse thy-1 and its human homologue. Fed Proc 41, 1982. e-Pub 1982.
105. Roper M, Gockerman JP, Balch CM. Natural killer (NK) cells in acute and chronic graft vs. host disease following bone marrow transplantation (BMT). Blood 60, 1982. e-Pub 1982.
106. Abo T, Gartland GL, Cooper MD, Balch CM. A comparison of two distinct phenotypes of human NK cells. Fed Proc 41, 1982. e-Pub 1982.
107. Dougherty PA, Balch CM. Special requirements for isolating purified lymphocyte populations in infected patients. Fed Proc 40, 1981. e-Pub 1981.
108. Abo T, Cooper MD, Balch CM. Morphology, development and distribution of human NK cells identified by a monoclonal antibody (HNK-1). Pediatr Res 15, 1981. e-Pub 1981.
109. Tilden AB, Balch CM. Modulation of mitogen response by indomethacin in melanoma patients is not related to prostaglandin E2. Fed Proc 40, 1981. e-Pub 1981.
110. Budowle B, Balch CM, Barger BO, Go RCP, Roseman JM, Acton RT. Properdin factor B in malignant melanoma. ASCO/AACR 22, 1981. e-Pub 1981.
111. Abo T, Balch CM. An antigen expressed on human NK and K cells identified by a monoclonal antibody (HNK-1). Fed Proc 40, 1981. e-Pub 1981.
112. Balch CM, Murray DR, Presant CA, Bartolucci AA, Study Group TSC. A randomized evaluation of adjunctive chemo-immunotherapy versus immunotherapy inpatients with resected metastatic melanoma. Int J Radiat Oncol Biol Phys 7, 1981. e-Pub 1981.
113. Balch CM, Dougherty PA, Tilden AB. Excessive prostaglandin E2 production by suppressor cells in head and neck cancer patients. ASCO/AACR 22, 1981. e-Pub 1981.
114. Barger BO, ActonRT, S-J S, Roseman CM, Balch CM, Crist W. The association of HLA-DR4 with malignant melonma in a Caucasian population from the southern U.S. ASCO/AACR 22, 1981. e-Pub 1981.
115. Dougherty PA, Balch CM. Differential response to tetanus toxoid among T cell subpopulations. Fed Proc 39, 1980. e-Pub 1980.
116. Acton RT, Barger BO, Murphy K, Roseman JM, Ingals AL, Balch CM. Apparent association of HLA antigens with melanoma. ASCO/AACR 21, 1980. e-Pub 1980.
117. Balch CM, S-J S, Murad TM, Maddox WA. Prognostic factors analysis of melanoma patients with regional lymph node metastases (stage II). ASCO/AACR 21, 1980. e-Pub 1980.
118. Ades EW, Shore S, Dougherty PA, Balch CM. Detection of T cell markers on killer (K) cells that mediate antibody dependent cellular cytotoxicity (ADCC). Fed Proc 38, 1979. e-Pub 1979.
119. Bukacek A, Roper M, Balch CM. A subpopulation of human T cells bearing Fc receptors for IgG can be induced by Con A to suppress the mixed lymphocyte reaction (MLR). Fed Proc 38, 1979. e-Pub 1979.
120. Dougherty PA, Loken M, Balch CM. Human t helper cells for PWM induced B cell differentiation can be distinguished by surface xenoantigens. Fed Proc 38, 1979. e-Pub 1979.
121. Presant CA, Bartolucci AA, Balch CM. Cyclophosphamide (C) plus DTIC (D) alone or with Piperazinedione (P) in melanoma. ASCO/AACR 20, 1979. e-Pub 1979.
122. Balch CM, Loken M, Ades EW, Dougherty PA, Shore SL. Further evidence that non-rosetting K cells express human T cell differentiation antigens. ASCO/AACR 20, 1979. e-Pub 1979.
123. Ades EW, Doughtery PA, Balch CM. Surface receptor expression on human null cells (E-rosette negative negative, slg negative). J Reticuloendothel Soc 24, 1979. e-Pub 1979.
124. Balch CM, Ades EW, Vogler L, Ferrone S. Comparative analysis of human B-cell differentiation xenoantigen with known DR (Ia-like) antigens. Fed Proc 37, 1978. e-Pub 1978.
125. Ades EW, Balch CM, Zwerner RK, Acton RT, Durant JR. Immunochemical characterization of two antigenic components on human normal and cultured T lymphocytes. ASCO/AACR 19, 1978. e-Pub 1978.
126. Dougherty PA, Ades EW, Balch CM. Detection of differentiation antigens distinct from E-rosette receptors on PHA-stimulated human T lymphocytes. Fed Proc 37, 1978. e-Pub 1978.
127. Balch CM, Vogler LB, Dougherty PA. Distribution and immunochemical properties of a unique B-cell differentiation antigen on human leukemic lymphocytes. ASCO/AACR 19, 1978. e-Pub 1978.
128. Balch CM, Murad TM, Maddox WA, Griffin AL, S-J S, Halpern NB. Prognostic value of histopathologic staging or cutaneous melanoma. Lab Invest 38, 1978. e-Pub 1978.
129. Ades EW, Dougherty PA, Ferrone S, Balch CM. Immunochemical identification of a new differentiation antigen on human B lymphocytes. J Reticuloendothel Soc 23, 1978. e-Pub 1978.
130. Balch CM, Dougherty PA, Vogler L, Cresswell P. Fluorescent detection of a human B-cell differentiation antigen (Ag) on normal and. Fed Proc 36, 1977. e-Pub 1977.
131. Balch CM, Dougherty PA. Distribution of human T cells and T cell antigens. Fed Proc 35, 1976. e-Pub 1976.
132. Balch CM, Dagg MK, Lawton AR, Cooper MD. Fluorescent anti-human T cell reagents from monkey and human sources. Fed Proc 34, 1975. e-Pub 1975.
133. Dubovsky EV, Logic JR, Balch CM, Dahlke C, Tauxe WN. Radionuclide evaluation of renal function in donors and recipients of renal transplants. South Med J 67, 1974. e-Pub 1974.
134. Balch CM, Feldman JD. The bone marrow origin of rat T lymphocytes demonstrated by combined immunofluorescence (IF) and autoradiography (AR). Fed Proc 32, 1973. e-Pub 1973.

Book Chapters

1. Gershenwald, JE, Thompson, JF, Mozzillo, N, Balch, CM. Intraoperative mapping and sentinel node technology in patients with melanoma, 415-446, 2024.
2. McMasters, KM, Wong, SL, Tyler, DS, Balch, CM, Thompson, JF. Axillary and epitrochlear lymph node dissection for melanoma, 447-456, 2024.
3. Thompson, JF, Morton, DL, Balch, CM, Ross, MI. Surgical excision of distant melanoma metastases, 603-628, 2024.
4. Jacobs, L, Balch, CM, Coit, D. Inguinofemoral, iliac/obturator, and popliteal lymphadenectomy in patients with melanoma, 457-470, 2024.
5. Tanabe, KK, Reintgen, DS, Balch, CM. Local recurrences of melanoma and their management, 323-336, 2024.
6. Balch, CM, Gershenwald, JE, Soong, SJ, Sober, A, Kirkwood, JM. Melanoma staging and classification, 65-86, 2024.
7. Gershenwald, JE, Balch, CM, Soong, SJ, Thompson, JF. Prognostic factors and natural history of melanoma, 35-64, 2024.
8. Atkins, MB, Hauschild, A, Wahl, RL, Balch, CM. Diagnosis of stage IV melanoma, 573-602, 2024.
9. Soong, SJ, Ding, S, Coit, D, Balch, CM. Models for predicting melanoma outcome, 87-104, 2024.
10. Balch CM, Shanafelt TD. The Role of Leaders, Supervisors and Individual Surgeons In Reducing Burnout and Promoting Physician Wellness. In: Mentorship and Leadership: Building for Success in Academic Surgery, 2017.
11. Balch CM, Delman K, Balch GC. The Management of Melanoma. In: Current Surgical Therapy. Elsevier Pub, 2016.
12. Balch CM, Balch GC, Thompson JF. Surgical Management of Metastatic Melanoma (Stages III and IV). In: Complex Surgical Oncology Textbook. McGraw Hill, 2015.
13. Balch CM, Thompson JF, Faries MB. The Clinical Value of Sentinel Node Biopsy for Melanoma Staging and for Improving Survival Rates in Melanoma Patients. In: the Melanoma Letter, 2015.
14. Balch CM, Morita S. Defining the Specialty of Surgical Oncology. In: Complex Surgical Oncology Textbook. McGraw Hill, 2015.
15. Balch CM, Sharma RR, Balch GC, Thompson JF. Melanoma Staging. In: Complex Surgical Oncology Textbook. McGraw Hill, 2015.
16. Balch CM. Forward. In: Melanoma. Prevention, Diagnosis, and Treatment. Atheneu, 2014.
17. Balch CM. Forward. In: Success in Academic Surgery: Clinical Trials. Springer, 2014.
18. Sharma RR, Balch GC, Balch CM. Evolution of the Melanoma Staging System. In: Emerging Cancer Therapies, Melanoma. Demos Medical Publishing, 405-420, 2012.
19. Nading MA, Balch CM, Sober AJ. Implications of the 2009 American Joint Committee on Cancer and Melanoma Staging and Classification on Dermatologists and Their Patients. In: Seminars in Cutaneous Medicine and Surgery. Seminars in Cutaneous Medicine and Surgery, 142-147, 2010.
20. Balch CM, Shanafelt T. Combating stress and burnout in surgical practice: A review. In: Advances in Surgery. Elsevier, 29-47, 2010.
21. Lange JR, Jain A, Balch G, Balch CM. Staging and treatment options for cutaneous melanoma. In: General Surgery. 2nd. Springer, 2010.
22. McMasters KM, Tyler DS, Balch CM. Axillary and Epitrochlear Lymph Node Dissection. In: Cutaneous Melanoma. 5th. Quality Medical Publishing, 2009.
23. Tanabe KK, Reintgen DS, Balch CM. Local Recurrences of Melanoma and Their Management. In: Cutaneous Melanoma. 5th. Quality Medical Publishing, 2009.
24. Ross MI, Byrd D, Balch CM, Cascinelli N. Excision of Primary Melanoma. Ch. 12. In: Cutaneous Melanoma. 5th. Quality Medical Publishing, 2009.
25. Balch CM, Gershenwald JE, Soong SJ, Sober A, Kirkwood J. Melanoma Staging and Classification. In: Cutaneous Melanoma. 5th. Quality Medical Publishing, 2009.
26. Gershenwald JE, Balch CM, Soong SJ, Thompson JF, Coit. Prognostic Factors and Natural History of Melanoma. Ch. 3. In: Cutaneous Melanoma. Quality Medical Publishing, 2009.
27. Balch CM. Melanoma Staging System for Cutaneous Melanoma. In: AJCC Cancer Staging Manual. 7th. Springer, 2009.
28. Balch CM, Gershenwald JE, Soong SJ. Melanoma of the Skin. In: AJCC Cancer Staging Manual, Ch. 31. Springer, 325-344, 2009.
29. Jacobs L, Lange J, Balch CM. Roses: Evolution of Elective Lymph Node Dissection for Cutaneous Malignant Melanoma. In: Surgical oncology: multidisciplinary approach to difficult problems. Lippincott, 2009.
30. Balch CM. Preface. In: Principles and Practice of Surgical Oncology: Multidisciplinary Approach to Difficult Problems. Lippincott, 2009.
31. Balch CM. Patient Resource: Cancer Guide: Treatment-Related Side Effects. In: Patient Resource Publishing. Patient Resource Publishing, 1-25, 2009.
32. S-J S, Ding S, Coit DG, Balch CM. Models for Predicting Melanoma Outcome. In: Cutaneous Melanoma. 5th. Quality Medical Publishing, 2009.
33. Thompson JF, Morton DL, Essner R, Balch CM. Surgical Excision of Distant Melanoma Metastases. In: Cutaneous Melanoma. 5th. Quality Medical Publishing, 2009.
34. Atkins M, Hauschild A, Wahl R, Balch CM. Diagnosis of Stage IV Melanoma. Ch 29. In: Cutaneous Melanoma. 5th. Quality Medical Publishing, 2009.
35. Coit DG, Jacob L, Balch CM, Thompson JF. Inguinofemoral, Iliac/Obturator, and Popliteal Lymphadenectomy in Patients with Melanoma. Ch 22. In: Cutaneous Melanoma. 5th. Quality Medical Publishing, 2009.
36. Gershenwald JE, Thompson JF, Mozzillo N, Balch CM. Intraoperative Mapping and Sentinel Node Technology in Patients with Melanoma. Ch. 20. In: Cutaneous Melanoma. 5th. Quality Medical Publishing, 2009.
37. Redett RJ, Balch CM. Melanoma. In: General Surgery Review. 2nd. Ladner-Drysdale, 357-362, 2008.
38. Lange JR, Balch CM. Melanoma in Older Patients. In: ASCO Educational Book. American Society of Clinical Oncology, 2008.
39. Lange JR, Jain A, Balch G, Balch CM. Staging and treatment options for cutaneous melanoma. In: Principles and International Practice. Springer-Verlag, 2008.
40. Lange JR, Fecher L, Sharfman WH, Alani RM, Mikkilineni R, Topalian SL, Balch CM. Melanoma. In: Clinical Oncology. 4th. Elsevier, 1229-1270, 2008.
41. Shockney LD, Balch C. Long-term follow-up of breast cancer survivors. In: The Johns Hopkins Breast Cancer Handbook for Health Care Professionals. Jones and Bartlett Publishers, 197-211, 2008.
42. Lange JR, Balch CM. Cutaneous melanoma. In: Clinical Scenarios in Surgical Oncology. Lippincott, 303-306, 2006.
43. Lange JR, Sharman WH, Alani RM, Balch CM. Melanoma. In: Clinical Oncology. 3rd. Elsevier Churchill Livingston Publishing, 1561-1588, 2004.
44. Balch CM, Sober AJ, Adkins M. Cutaneous melanoma. In: Textbook of Oncology, 157, 2004.
45. Lange JR, Balch CM. Skin and Soft Tissue: Cutaneous Melanoma. In: Current Surgical Therapy. 8th. Elsevier Mosby Publishers, 1052-1056, 2004.
46. Balch CM, S-J S, Thompson JF. The Natural History of Melanoma and Factors Predicting Outcome. In: Textbook of Melanoma. Martin Dunitz Publisher, 181-198, 2004.
47. Balch CM Miller SJ. Biopsy. In: Cutaneous Melanoma. 4th. Quality Medical Publishing, 163-170, 2003.
48. Balch CM, Cascinelli N, Sim FH. Elective Lymph Node Dissection: Results of Prospective Randomized Surgical trials. In: Cutaneous Melanoma. 4th. Quality Medical Publishing, 379-396, 2003.
49. Balch CM, Coit DG. Groin and Popliteal Dissections: Technique and Complications. In: Cutaneous Melanoma. 4th. Quality Medical Publishing, 405-418, 2003.
50. Balch CM, Hwu WJ, Houghton AN. Diagnosis of Stage IV Disease. In: Cutaneous Melanoma. 4th. Quality Medical Publishing, 523-546, 2003.
51. Balch CM, Morton DL, Essner R. Surgical Excision of Distant Metastases. In: Cutaneous Melanoma. 4th. Quality Medical Publishing, 547-572, 2003.
52. Balch CM, McMasters KM, Wong SL, Tyler DS. Axilary and Epitrochlear Lymph Node Dissection. In: Cutaneous Melanoma. 4th. Quality Medical Publishing, 397-404, 2003.
53. Balch CM, Tanabe KK, Reintgen DS. Management of Localized Melanoma. In: Cutaneous Melanoma. 4th. Quality Medical Publishing, 209-230, 2003.
54. Balch CM, Gershenwald JE, Soong SJ, Thompson JF. Prognostic Factors and Natural History. In: Cutaneous Melanoma. 4th. Quality Medical Publishing, 29-54, 2003.
55. Balch CM, Gershenwald JE, Soong SJ, Buzaid AC, Cascinelli N. Staging and Classification. In: Cutaneous Melanoma. 4th. Quality Medical Publishing, 55-76, 2003.
56. Balch CM, Lange JR, Gershenwald JE. Staging and Selection of Treatment Options for Melanoma. In: The Practice of General Surgery. W.B. Saunders, 1003-1009, 2002.
57. Balch CM, S-J S, Thompson JF, Buzaid A. Prognostic Factors and Staging in Melanoma. In: Progress in Oncology. Jones and Bartlett Publishers, 215-250, 2002.
58. Balch CM. Management of Regional Lymph Nodes in Patients with Cutaneous Melanoma. In: Surgical Oncology: Multidisciplinary approach to difficult problems. Edward Arnold Pub, 434-440, 2002.
59. Balch CM. Commentary on Non-Surgical Treatment of Melanoma. In: Crucial Controversies in Surgery. 6th. Lippincott, 209-220, 2002.
60. Balch CM. Commentary on Sentinel Lymphadenectomy Tyler, Siegler. In: Crucial Controversies in Surgery. Lippincott, 2002.
61. Balch CM Lange JR. Surgical Aspects. In: Sentinel Lymph Node Biopsy. Martin Dunitz Publisher, 71-78, 2002.
62. Balch CM, S-J S, Thompson JF. The Natural History and Prognostic Factors. Predicting Outcome of Melanoma. In: Cutaneous Melanoma, 2002.
63. Balch CM. AV Communication as a Research Skill. In: Surgical Research. Academic Press, 1237-1240, 2001.
64. Balch CM, Silverstein MJ. Use of drains and prophylactic antibiotics in breast surgery. In: Advances in Surgery. Mosby, 1-15, 2000.
65. Balch CM. Randomized surgical trials involving elective node dissection for melanoma. In: Advances in Surgery. Mosby, 255-270, 1999.
66. Balch CM, Dodd Jr GD, Henderson IC, Perez CA, Singletary SE. Breast Diseases: Milestones of the Past Decade. In: Breast Diseases: A Year Book Quarterly, 1999.
67. Pollock RG, Balch CM, Roth J, McPeek B, Mosteller F. Formulating an initial research plan. In: Surgical Research: Basic Principles and Clinical Practice. 3rd. Springer-Verlag, 363-366, 1998.
68. Balch CM. Foreword. In: The M.D. Anderson Surgical Oncology Handbook. Little, Brown and Company, 1998.
69. Balch CM. Surgical treatment of advanced melanoma. In: Cutaneous Melanoma. 3rd. Quality Medical Publishing, 1998.
70. Meyers ML, Balch CM. Diagnosis and treatment of metastatic melanoma. In: Cutaneous Melanoma. 3rd. Quality Medical Publishing, 1998.
71. Mansfield PF, Ames FC, Balch CM. Axillary lymph node dissection. In: Cutaneous Melanoma. 3rd. Quality Medical Publishing, 1998.
72. Balch CM, Cascinelli N, Sim FH, S-J S, Taylor WF, Bufalina R. Elective lymph node dissection: results of prospective randomized surgical trials. In: Cutaneous Melanoma. 3rd. Quality Medical Publishing, 1998.
73. Karakousis CP, Bartolucci AA, Balch CM. Local recurrence and its management. In: Cutaneous Melanoma. Quality Medical Publishing, 1998.
74. Ross MI, Balch CM. Surgical treatment of primary melanoma. In: Cutaneous Melanoma. 3rd. Quality Medical Publishing, 1998.
75. Ho VC, Sober AF, Balch CM. Biopsy techniques. In: Cutaneous Melanoma. 3rd. Quality Medical Publishing, 1998.
76. Stadelmann WK, Rapaport DP, S-J S, Reintgen DS, Buzaid AC, Balch CM. Prognostic clinical and pathologic features. In: Cutaneous Melanoma. 3rd. Quality Medical Publishing, 1998.
77. Balch CM. Randomized Surgical Trials Involving Melanoma Management. In: General Motors Cancer Research Foundation: Accomplishments in Cancer Research. J.B. Lippincott, 173-179, 1998.
78. Balch CM, McKneally MF, McPeek B Mulder DS, Spitzer WO, Troidl H, Weschler AS. Pentathlete: the many roles of an academic surgeon. In: Basic Principles and Clinical Practice. 3rd. Springer-Verlag, 615-622, 1998.
79. Pollock RG, Niederhuber JE, Balch CM. Applying for funding from the NIH: A useful paradigm for most applicants. In: Surgical Research: Basic Principles and Clinical Practice. 3rd. Springer-Verlag, 383-390, 1998.
80. Pollock RG, Balch CM, Holmes EC. Multicenter collaborative clinical trials. In: Surgical Research: Basic Principles and Clinical Practice. 3rd. Springer-Verlag, 211-222, 1998.
81. Balch CM. Team Approach to Cancer Management. In: Reconstructive Plastic Surgery. Mosby, 685-700, 1997.
82. Coit D, Wallack M, Balch C. Society of Surgical Oncology practice guidelines. In: Melanoma surgical practice guidelines, 1317-23, 1997.
83. Balch CM, Lee JE, Singletary SE. Reoperations for melanoma. In: Reoperative in General Surgery. 11. Mosby Year Book, 685-700, 1997.
84. Balch CM, Reintgen D, Kirkwood JM, Houghton A, Peters L, Ang KK. Cutaneous melanoma. In: Cancer: Principles and Practice of Oncology. 13-60, 1996.
85. Balch CM. Foreword. In: The M.D. Anderson Surgical Oncology Handbook. Little, Brown and Company, 1995.
86. Curley SA, Balch CM. Hepatic arterial infusion therapy. In: Current Surgical Therapy. 5th. Mosby Year Book, 1994.
87. Pellis NR, Balch CM. Basic concepts in immunology. In: Current Practice of Surgery. Williams & Wilkins, 112-136, 1993.
88. Yeatman TJ, Weber RS, Balch CM. The contemporary management of skin cancers. In: Current Practice of Surgery, 1-27, 1993.
89. Balch CM, Pellis NR, Morton DL, Eifel PJ, Brennan MF. Oncology. In: Principles of Surgery. 6th. McGraw Hill Publ, 305-376, 1993.
90. Balch CM, Houghton AN, Peters LJ. Cutaneous melanoma. In: Cancer: Principles and Practice of Oncology. 2nd. J.B. Lippincott, 1612-1678, 1993.
91. Balch CM, Ross MI. Clinical management of cutaneous melanoma. In: Cancer Surgery. J.B. Lippincott, 551-576, 1993.
92. Steele G, Ravikumar TS, Balch CM. Biology and immunology of neoplasia. In: Surgical Basic Science. Mosby Year Book, 1-30, 1993.
93. Fitzpatrick TB, Milton GW, Balch CM, Shaw HM, McCarthy WH, Sober AJ. Clinical characteristics of melanoma. In: Cutaneous Melanoma. 2nd. J.B. Lippincott, 468-497, 1992.
94. Balch CM, Hougton A. Diagnosis of metastatic melanoma at distant sites. In: Cutaneous Melanoma. 2nd. J.B. Lippincott, 439-467, 1992.
95. Ross M, Balch CM. General principles of regional lymphadenectomy. In: Cutaneous Melanoma. 2nd. J.B. Lippincott, 339-344, 1992.
96. Singletary SE, Balch CM. Recurrent reginal metastases and their management. In: Cutaneous Melanoma. 2nd. J.B. Lippincott, 427-435, 1992.
97. Urist MM, Balch CM. Head and Neck Melanoma. In: Cutaneous Melanoma. 2nd. J.B. Lippincott, 295-301, 1992.
98. Singletary SE, Sutherland CM, Balch CM. Melanoma and pregnancy. In: Cutaneous Melanoma. 2nd. J.B. Lippincott, 319-324, 1992.
99. Ames FC, Balch CM, McCarthy WH. Axillary lymph node dissection. In: Cutaneous Melanoma. 2nd. J.B. Lippincott, 384-391, 1992.
100. Singletary SE, Balch CM, Urist MM, McCarthy WH, Cascinelli N. Surgical treatment of primary melanoma. In: Cutaneous Melanoma. 2nd. J.B. Lippincott, 269-274, 1992.
101. Ames FC, Balch CM, Reintgen D. Local recurrence and their management. In: Cutaneous Melanoma. 2nd. J.B. Lippincott, 287-294, 1992.
102. Balch CM, Milton GW, Cascinelli N, Sim FH. Elective lymph node dissection: Pros and Cons. In: Cutaneous Melanoma. 2nd. J.B. Lippincott, 345-366, 1992.
103. Pellis N, Byrd DR, Talamonti MS, Balch CM. Tumor Biology. In: Surgery: Scientific Principles and Practice. J.B. Lippincott, 407-460, 1992.
104. Balch CM, S-J S, Shaw H. Changing trends in the clinical and pathologic features of melanoma. In: Cutaneous Melanoma. 2nd. J.B. Lippincott, 40-45, 1992.
105. Itoh K, Houghton AN, Balch CM. Immune responses to melanoma. In: Cutaneous Melanoma. 2nd. J.B. Lippincott, 144-162, 1992.
106. Balch CM, S-J S, Shaw H, Urist M, McCarthy WH. An analysis of prognostic factors in 8,500 patients with cutaneous melanoma. In: Cutaneous Melanoma. 2nd. J.B. Lippincott, 165-187, 1992.
107. Balch CM, S-J S. A comparison of prognostic factors and treatment results worlwide. In: Cutaneous Melanoma. 2nd. J.B. Lippincott, 188-199, 1992.
108. Ketcham AS, Moffat FL, Balch CM. Classification and staging. In: Cutaneous Melanoma. 2nd. J.B. Lippincott, 213-233, 1992.
109. Houghton AN, Balch CM. Treatment for advanced melanoma. In: Cutaneous Melanoma. 2nd. J.B. Lippincott, 468-497, 1992.
110. Itoh K, Balch CM. Properties of human tumor infiltrating lymphocytes. In: Therapeutic Applications of Interleukin-2. Marcel Dekker, 39-48, 1992.
111. Itoh K, Balch CM, von Eschenbach AC, Morita T, Hayakawa K, Seito D. Human tumor-infiltrating lymphocytes. In: Human tumor-infiltrating lymphocytes. 117-123. Gann Monograph, 1992.
112. Balch CM, Polk HC. Skin and soft tissue lesions. In: Quality Medical Publishing. Quality Medical Publishing, 595-605, 1992.
113. Balch CM, McKneally MF, McPeek B, Mulder DS, Spitzer WO, Troidl H, Wechsler AS. The academic surgeon. In: Principles and Practice of Research. 2nd. Springer-Verlag, 25-30, 1991.
114. Pollock RE, Niederhuber J, Balch CM. Writing grant applications for laboratory research. In: Principles and Practice of Research. 2nd. Springer-Verlag, 220-228, 1991.
115. Wechsler AS, McKneally MF, Balch CM, Mosteller F, McPeek B, Mulder DS. Strengthening the research environment. In: Principles and Practice of Research. 2nd. Springer-Verlag, 31-40, 1991.
116. McKneally MF, Troidl H, Mulder DS, Spitzer WO, McPeek B, Balch CM, Wechsler AS. Common characteristics and distinctive diversity in surgical research. In: Principles and Practice of Research. 2nd. Springer-Verlag, 530-540, 1991.
117. Balch CM, Singletary SE. Malignant melanoma. In: Textbook on Clinical Oncology. ASC, 263-270, 1991.
118. Balch CM McKneally MF, McPeek B, Mulder DM, Spitzer WO, Troidl H, Wechsler AS. How to review manuscripts. In: Principles and Practice of Research. 2nd. Springer-Verlag, 414-419, 1991.
119. Pollock RE, Balch CM, Roth J, McPeek B, Mosteller F. Formulating an initial research plan. In: Principles and Practice of Research. 2nd. Springer-Verlag, 88-90, 1991.
120. Margolese RG, Balch CM. Multicenter collaborative clinical trials. In: Principles and Practice of Research. 2nd. Springer-Verlag, 530-540, 1991.
121. Balch CM. The surgical management of cutaneous melanoma. In: Progress in Cancer Surgery. Mosby Year Book, 292-310, 1991.
122. Balch CM, Pellis N. Clinical immunology and biological therapy of human cancer. In: Proceedings from the 1990 Surgical Research and Education Symposium. American Cancer Society, 13-23, 1991.
123. Evans M, Pollock AV, Wiggin NJB, Balch CM. Writing your first scientific paper. In: Principles and Practice of Research. 2nd. Springer-Verlag, 1991.
124. Legha SW, Ring D, Balch CM, Plager C, Papadopoulos N, Singletary SE, Benjamin RS. Induction chemotherapy for the treatment of patients with stage II malignant melanoma. In: Adjuvant Therapy. W.B. Saunders, 586-592, 1991.
125. Balch CM, Broadwater JR, Singletary SE. Reoperations for melanoma. In: Reoperations in General Surgery: Timing, Tactics and Techniques. Year Book Medical Publishers, 1991.
126. Singletary SE, Balch CM. Melanoma surgery. In: Current Therapy in Hematology Oncology. Academic Press, 887-891, 1991.
127. Pollock RE, Kroll SS, Balch CM. Surgical procedures for advanced local and regional malignancy of the breast. In: The Breast. W.B. Saunders, 948-956, 1990.
128. Fossati G, Balch CM. Immunobiology of melanoma in man. In: Cutaneous Melanoma: Biology and Management. Masson, 153-158, 1990.
129. Ames F, Balch CM. Management of local and regional recurrence after mastectomy or breast-conserving treatment. In: The Surgical Clinics of North America. W.B. Saunders, 1115-1124, 1990.
130. Ross M, Balch CM. The current management of melanoma. In: Advances in Surgery. Mosby Year Book, 139-200, 1990.
131. Itoh K, Balch CM. Regulation by soluble mediators. In: Role of Interleukin 2-Activated Killer Cells in Cancer. CRC Press, 65-88, 1990.
132. Singletary SE, Balch CM. Malignant melanoma. In: Encyclopedia of Human Biology, 1990.
133. Broadwater JR, Edwards MJ, Ross MI, Balch CM. Cancer care: A proposal for increased surgical oncology exchange between the United States and Soviet Union. In: Foreign Policy Briefs. Johns Hopkins FPI, 1-10, 1989.
134. Urist MM, Balch CM. Melanoma. In: Current Surgical Therapy. B.C. Decker, 744-748, 1989.
135. Broadwater JR, Edwards MJ, Ross MI, Balch CM. Cooperation in surgical oncology. In: The Future of U.S. Soviet Relations. United Press of America, 207-216, 1989.
136. Balch CM. Cutaneous melanoma of the lower thigh: Should treatment be wide excision and prophylactic femoral node dissection?. In: Common Problems in Cancer Surgery. Year Book Medical Publishers, 292-297, 1989.
137. Balch CM, Urist MM, Byers RM. Prognostic factors in head and neck melanoma and their implications in treatment planning. In: Head and Neck Oncology Research. Kugler and Ghedini, 206-210, 1989.
138. Edwards MJ, Balch CM. Surgical Aspects of Lymphoma. In: Advances in Surgery, 225-250, 1989.
139. Balch CM. How to organize a clinical research program. In: CCSR Proceedings of the 1988 Grantsmanship Symposium, 11-26, 1989.
140. Broadwater JR, Balch CM. Mass in the Neck. In: Current Surgical Therapy. B.C. Decker, 754-757, 1989.
141. Balch CM, Houghton A, Peters LJ. Cutaneous melanoma. In: Cancer: Principles and Practice of Oncology. J.B. Lippincott, 1499-1542, 1989.
142. Balch CM, Wilson RE. Immunity in the immunocompromised surgical patient. In: The Physiologic Basis of Modern Surgical Care. C.V. Mosby, 71-88, 1988.
143. Balch CM. The skin and subcutaneous tissues: Melanoma and other lesions. In: Hardy's Textbook of Surgery. J.B. Lippincott, 313-320, 1988.
144. Balch CM. The role of surgery in the treatment of cancer metastases. In: Accomplishments in Cancer Research. J.B. Lippincott, 203-215, 1987.
145. Cascinelli N, Bajetta E, Santinami E, buzzoni R, Balch CM, Peter H, Bernego MG. Adjuvant therapy: Has it a role?. In: Cutaneous Melanoma: Status of Knowledge and Future Perspective. Academic Press, 563-575, 1987.
146. Balch CM, Urist MM. Regional infusion for primary hepatic carcinomas. In: Cancer Chemotherapy by Infusion. Prcept Press, 447-454, 1987.
147. Cascinelli N, Santinami M, Goldsmith HS, Balch CM. Indications for dissection of regional nodes. In: Cutaneous Melanoma: Status of Knowledge and Future Perspective. Academic Press, 555-561, 1987.
148. Balch CM. Melanoma. In: Current Surgical Therapy. B.C. Decker and C.V. Mosby, 487-492, 1986.
149. Urist MM, S-J S, Balch CM. Multifactorial considerations in the treatment of melanoma of the head and neck. In: Treatment of Metastatic Cancer of the Head and Neck. MacMillan, 225-233, 1986.
150. Balch CM, Hersey P. Current status of adjuvant therapy. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. J.B. Lippincott, 197-218, 1985.
151. Balch CM, Urist MM, Maddox WA, S-J S. Melanoma in the Southern United States: Experience at the University of Alabama in Birmingham. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. J.B. Lippincott, 397-406, 1985.
152. Balch CM, Mettlin C. Melanoma in the United States: A national survey of 4800 patients. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. J.B. Lippincott, 389-395, 1985.
153. Balch CM, S-J S, Shaw HM, Milton GW. Analysis of prognostic factors in 4000 patients with cutaneous melanoma. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. J.B. Lippincott, 321-352, 1985.
154. Balch CM, Soong S-J SH, Milton GW. Changing trends in the clinical and pathological features of melanoma. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. J.B. Lippincott, 313-319, 1985.
155. Balch CM, Milton GW. Treatment for advanced melanoma. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. J.B. Lippincott, 251-273, 1985.
156. Balch CM, Milton GW. Diagnosis of metastatic melanoma at distant sites. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. J.B. Lippincott, 221-250, 1985.
157. Balch CM, S-J S, Shaw HM. A comparison of worldwide melanoma data. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. J.B. Lippincott, 507-518, 1985.
158. Logic JR, Balch CM. Defining lymphatic drainage patterns with cutaneous lymphoscintigraphy. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. J.B. Lippincott, 159-170, 1985.
159. Balch CM, Milton GW, Cascinelli N, Sim FH. Elective lymph node dissection: Pros and cons. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. J.B. Lippincott, 131-157, 1985.
160. Balch CM. Clinical management of cutaneous melanoma. In: Fundamentals of Surgical Oncology. MacMillan, 1985.
161. Balch CM, Urist MM, Maddox WA, Milton GW, McCarthy WA. Management of regional metastatic melanoma. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. J.B. Lippincott, 93-130, 1985.
162. Urist MM, Balch CM, Milton GW. Surgical management of the primary melanoma. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. J.B. Lippincott, 71-90, 1985.
163. Ketcham AS, Balch CM. Classification and staging systems. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. J.B. Lippincott, 55-62, 1985.
164. Milton GW, Balch CM, Shaw HM. Clinical characteristics. In: Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. J.B. Lippincott, 13-28, 1985.
165. Balch CM. Surgical treatment for metastatic melanoma at distant sites. In: Pigment Cell. Karger Publishers, 1985.
166. Abo T, Balch CM. The use of monoclonal antibodies to characterize human NK cell ontogeny and function. In: Autoimmunity Probed by Monoclonal Antibodies. Academic Press, 97-113, 1984.
167. Balch CM. Surgical management of melanoma. In: Current Surgical Therapy. C.V. Mosby, 1984.
168. Balch CM. Cutaneous melanoma. In: Textbook of Surgery: Basic Principles and Practice. J.B. Lippincott, 304-310, 1983.
169. Cooper MD, Abo T, Kamps WA, Haber PL, Balch CM. Subpopulations of human lymphocytes and their alterations in immunodeficiency diseases. In: Immunoregulation. Plenum Press, 13-24, 1983.
170. Warner NL, Lanier LL, Walker E, Stewart C, Wood G, Balch CM. Hematopic tumors: Normal or abnormal models of leukocyte differntiation. In: Hybridomas and Cellular Mortality. Plenum Press, 27-44, 1983.
171. Acton RT, Balch CM, Barger BO, Budowle B, Go RCP, S-J S, Roseman JM. The occurrence of melanoma and its relationship with host, lifestyle and environmental factors. In: Malignant Melanoma. The Hague: Martinus Nijhoff, 151-182, 1982.
172. Abo T, Cooper MD, Balch CM. Characterization of human NK cells identified by the monoclonal HNK-1 (Leu-7) antibody. In: NK Cells and Other Natural Effector Cells. Academic Press, 31-38, 1982.
173. Balch CM, S-J S. Characteristics of melanoma that predict the risk of metastases. In: Malignant Melanoma. The Hague: Martinus Nijhoff, 117-149, 1982.
174. Tilden AB, Doughtery PA, Balch CM. Differential effects of indomethacin and PGE2 on the depressed responses of cancer patients. In: Prostaglandins and Cancer. 1st International Conference, 651-655, 1982.
175. Balch CM, Tilden AB. Indomethacin, prostaglandin, and immune regulation in melanoma. In: Melanoma Antigens and Antibodies. Plenum Press, 23-25, 1982.
176. Acton RT, Balch CM, Budowle B, Go RCP, Roseman JM, S-J S, Barger BO. Immunogenetics of melanoma. In: Melanoma Antigens and Antibodies. Plenum Press, 1-21, 1982.
177. Ades EW, Doughtery PA, Balch CM. Partial immunochemical characterization of human B-lymphocyte differentiation antigen (BDA-1). Part B. In: Macrophages and Lymphocytes. Plenum Press, 239-246, 1980.
178. Costanzi JJ, Cunningham TJ, Balch CM. Malignant melanoma. In: Cancer Research: Impact of the Cooperative Groups. Masson, 227-246, 1980.
179. Ades EW, Balch CM. A molecular approach delineating surface markers on human T lymphocytes. In: Function and Structure of the Immune System. Plenum Press, 593-598, 1979.
180. Balch CM, S-J S, Murad TM, Ingalls AL, Maddox WA. Prognostic factors influencing survival of melanoma patients. In: Advances in Medical Oncology Research and Education. Pergamon Press, 77-85, 1979.
181. Schrohenloher RE, Balch CM, Volanakis JE. Detection of circulating immune complexes by radioimmunoassay with monoclonal rheumatoid factor: Comparison with C1q binding and RAJI cell radioassays in cancer. In: Protides of the Biological Fluids: Proc. 26th Colloquium. Pergamon Press, 43-46, 1979.
182. Balch CM. Adjuvant therapy after surgical resection. In: Surgical Companion of the Life Sciences. Van Nostrand Reinhold, 1979.
183. Ades EW, Doughtery PA, Balch CM. Partial immunochemical characterization of a human B lymphocyte differentiation antigen BDA-1. In: Adv Exp Med Biol, 239-245, 1979.
184. Balch CM, Lawton AR, Cooper MD. Preparation of heterologous antisera specific for human T cells. In: In vitro Methods in Cell-Mediated and Tumor Immunity. Academic Press, 105-111, 1976.
185. Balch CM, Dagg MK, Cooper MD. Phylogenetic relationships of T cell antigens among mammalian and avian species. In: Phylogeny of Thymus and bone Marrow-Bursa Cells. Elsevier/North Holland Biomedical Press, 287-394, 1976.

Books (edited and written)

1. Balch, CM, Houghton, A, Sober, A, Soong, SJ, Atkins, MB, Thompson, JF. Cutaneous melanoma, fifth edition, 2024.
2. Zhimin S, Cordeiro PG, Balch CM. Breast Cancer, First Edition, 2017.
3. Balch CM, Sober AJ, Halpern A, Atkins MB, Kirkwood J, Kefford R, Thompson JF, Gershenwald J. Cutaneous Melanoma. 6th edition. Springer, 2016.
4. Balch CM. Patient Resource: A Cancer Guide. 10th ed. Patient Resource Publishing, 2016.
5. Morita S, Balch CM, Klimberg VS, Pawlik T, Tanabe K. Textbook of Advanced Surgical Oncology. McGraw Hill Publ, 2016.
6. Balch CM. Patient Resource: Cancer Guide. 9th ed. Patient Resource Publishing, 2015.
7. Balch CM. Patient Resource: Cancer Guide. 8th ed. Patient Resource Publishing, 2014.
8. Balch CM. Patient Resource: Cancer Guide. 7th ed. Patient Resource Publishing, 2013.
9. Balch CM. Patient Resource: Cancer Guide. 6th ed. Patient Resource Publishing, 2012.
10. Balch CM. Patient Resource: Cancer Guide. 5th ed. Patient Resource Publishing, 2011.
11. Balch CM, Hortobagyi GN. Patient Resource: Breast Cancer Guide. 2nd ed. Patient Resource Publishing, 2010.
12. Balch CM. Patient Resource: A Cancer Guide. 4th ed. Patient Resource Publishing, 2010.
13. Balch CM, Hougton A, Sober A, S-J S, Atkins MB, Thompson JF. Cutaneous Melanoma. 5th Edition. Quality Medical Publishing, 2009.
14. Balch CM. Patient Resource: A Cancer Guide. 3rd ed. Patient Resource Publishing, 2009.
15. Balch CM. Patient Resource: A Cancer Guide. 2nd ed. Patient Resource Publishing, 2008.
16. Balch CM. Patient Resource: A Cancer Guide. Patient Resource Publishing, 2007.
17. Balch CM, Hougton A, Sober A, S-J S. Cutaneous Melanoma. 4th Edition. Quality Medical Publishing, 2003.
18. Greene FL, Page DL, Fleming ID, Fritz AG, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging Manual, 6th ed. Springer-Verlag, 2002.
19. Cameron JL, Balch CM, Langer B, Mannick JA, Sheldon GF, Shires GT, Tompkins RK, Welch CE. Advances in Surgery. Mosby, 1999.
20. Balch CM, Hougton A, Sober A, S-J S. Cutaneous Melanoma. 3rd ed. Quality Medical Publishing, 1998.
21. Cameron JL, Balch CM, Langer B, Mannick JA, Sheldon GF, Shires GT, Tompkins RK, Welch CE. Advances in Surgery. Mosby, 1998.
22. Cameron JL, Balch CM, Langer B, Mannick JA, Sheldon GF, Shires GT, Tompkins RK, Welch CE. Advances in Surgery. Mosby, 1997.
23. Cameron JL, Balch CM, Langer B, Mannick JA, Sheldon GF, Shires GT, Tompkins RK, Welch CE. Advances in Surgery. Mosby, 1996.
24. Cameron JL, Balch CM, Langer B, Mannick JA, Sheldon GF, Shires GT, Tompkins RK, Welch CE. Advances in Surgery. Mosby, 1995.
25. Cameron JL, Balch CM, Langer B, Mannick JA, Sheldon GF, Shires GT, Tompkins RK, Welch CE. Advances in Surgery. Mosby, 1994.
26. Cameron JL, Balch CM, Langer B, Mannick JA, Sheldon GF, Shires GT, Tompkins RK, Welch CE. Advances in Surgery. Mosby, 1993.
27. Balch CM, Hougton A, Milton GW, Sober A, S-J S. Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. J.B. Lippincott, 1992.
28. Cameron JL, Balch CM, Langer B, Mannick JA, Sheldon GF, Shires GT, Tompkins RK, Welch CE. Advances in Surgery. Mosby, 1992.
29. Cameron JL, Balch CM, Langer B, Mannick JA, Sheldon GF, Shires GT, Tompkins RK, Welch CE. Advances in Surgery. Mosby, 1991.
30. Troidl H, Spitzer WO, Mulder DS, Wechsler AS, McPeek B, McKneally MF, Balch CM. Principles and Practice of Research: Strategies for Surgical Investigators 2nd ed. Springer-Verlag, 1991.
31. Cameron JL, Balch CM, Langer B, Mannick JA, Sheldon GF, Shires GT, Tompkins RK, Welch CE. Advances in Surgery. Mosby, 1990.
32. Cameron JL, Balch CM, Langer B, Mannick JA, Sheldon GF, Shires GT, Tompkins RK, Welch CE. Advances in Surgery. Mosby, 1989.
33. Balch CM. Surgical Approaches to Cutaneous Melanoma. S. Karger AG, 1985.
34. Balch CM, Milton GW. Cutaneous Melanoma: Clinical Management and Treatment Results Worldwide. J.B. Lippincott, 1985.

Letters to the Editor

1. Guo J, Balch CM. Letter to the Editor Concerning "An Evidence-Based Staging System for Mucosal Melanoma: A Proposal," by Smith, Henry et al. Ann Surg Oncol.
2. Eton O, Legha SS, Balch CM. Cutaneous melanoma. N Engl J Med 365: 345-346, 1992.
3. Balch CM. Surgical controversies in melanoma. J Clin Oncol 6: 392-393, 1988.
4. Soong S, CCCM B. Multivariate analysis. JAMA 250: 2471-2472, 1983.